<html lang="en" class="pb-page js" data-request-id="94d656d4e3c0af23-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d656d4e3c0af23-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/YEE0e_5D2xoGDsKx5lRfb2Jye6SDQbTAceSE8mBpCPJDy9ZWojTZ4cpNz3oV78_3LjcMS4lRX4C2BYY8OgWN9g=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d656d4e3c0af23-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.1060620030632855"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Treatments in Oncology|Lung Cancer">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Hematology/Oncology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2027187","title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","category":"Research","type":"Original Article","topics":"Treatments in Oncology|Lung Cancer","specialties":"Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-11-19T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Treatments in Oncology|Lung Cancer\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2027187","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Quick Take","title":"Lorlatinib versus Crizotinib in Advanced ALK-Positive Lung Cancer","doi":"10.1056/NEJMdo005883","issueDate":"2020-11-19T00:00Z","age":"6Months-1990","isFree":"n","topics":"Treatments in Oncology|Lung Cancer","viewType":"Full","specialties":"Hematology/Oncology"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d656d4e3c0af23-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer"><meta name="dc.Creator" content="Alice T. Shaw"><meta name="dc.Creator" content="Todd M. Bauer"><meta name="dc.Creator" content="Filippo de Marinis"><meta name="dc.Creator" content="Enriqueta Felip"><meta name="dc.Creator" content="Yasushi Goto"><meta name="dc.Creator" content="Geoffrey Liu"><meta name="dc.Creator" content="Julien Mazieres"><meta name="dc.Creator" content="Dong-Wan Kim"><meta name="dc.Creator" content="Tony Mok"><meta name="dc.Creator" content="Anna Polli"><meta name="dc.Creator" content="Holger Thurm"><meta name="dc.Creator" content="Anna M. Calella"><meta name="dc.Creator" content="Gerson Peltz"><meta name="dc.Creator" content="Benjamin J. Solomon"><meta name="dc.Description" content="Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non–small-cell lung cancer (NSCLC). The efficac..."><meta name="Description" content="Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non–small-cell lung cancer (NSCLC). The efficac..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-11-19"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2027187"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202011193832109"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa2027187"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2027187">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2027187">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2027187">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM">
        <meta property="og:title" content="First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2027187">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/36201cc3-90d7-4f2c-af4e-53d9075534ee/nejmoa2027187_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/36201cc3-90d7-4f2c-af4e-53d9075534ee/nejmoa2027187_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has
antitumor activity in previously treated patients with ALK-positive non–small-cell
lung cancer (NSCLC). The efficac...">
        <meta name="twitter:description" content="Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has
antitumor activity in previously treated patients with ALK-positive non–small-cell
lung cancer (NSCLC). The efficac...">
    


    
    
        <meta property="og:image:width" content="2231">
    


    
    
        <meta property="og:image:height" content="3097">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2027187">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2027187">
    
    







<meta name="pbContext" content=";issue:issue:doi\:10.1056/nejm_2020.383.issue-21;requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2027187;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2027187" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2027187" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2027187" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2027187" class="inputDoi"><input type="hidden" value="A.T. Shaw and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:2018-2029" class="inputCitation"><input type="hidden" value="11-18-2020" class="inputEPubDate"><input type="hidden" value="November 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung Cancer" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d656d4e3c0af23-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung Cancer</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Alice T.</span> <span property="familyName">Shaw</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Todd M.</span> <span property="familyName">Bauer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Filippo</span> <span property="familyName">de Marinis</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Enriqueta</span> <span property="familyName">Felip</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yasushi</span> <span property="familyName">Goto</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Geoffrey</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Julien</span> <span property="familyName">Mazieres</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+7</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dong-Wan</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tony</span> <span property="familyName">Mok</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anna</span> <span property="familyName">Polli</span>, <span property="honorificSuffix">B.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Holger</span> <span property="familyName">Thurm</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anna M.</span> <span property="familyName">Calella</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gerson</span> <span property="familyName">Peltz</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Benjamin J.</span> <span property="familyName">Solomon</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the CROWN Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-7</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">November 18, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">2018</span>-<span property="pageEnd">2029</span></div><div class="doi">DOI: 10.1056/NEJMoa2027187</div><div class="core-enumeration"><a href="/toc/nejm/383/21"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">21</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAlice%2BT.%2BShaw%252C%2BTodd%2BM.%2BBauer%252C%2BFilippo%2Bde%2BMarinis%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D21%26contentID%3D10.1056%252FNEJMoa2027187%26title%3DFirst-Line%2BLorlatinib%2Bor%2BCrizotinib%2Bin%2BAdvanced%2B%253Ci%253EALK%253C%252Fi%253E-Positive%2BLung%2BCancer%26publicationDate%3D11%252F19%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2027187" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAlice%2BT.%2BShaw%252C%2BTodd%2BM.%2BBauer%252C%2BFilippo%2Bde%2BMarinis%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D21%26contentID%3D10.1056%252FNEJMoa2027187%26title%3DFirst-Line%2BLorlatinib%2Bor%2BCrizotinib%2Bin%2BAdvanced%2B%253Ci%253EALK%253C%252Fi%253E-Positive%2BLung%2BCancer%26publicationDate%3D11%252F19%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/fb5abbed-0af9-4c36-af78-89a4774ef4b0/nejmoa2027187.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2027187.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2027187" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2027187" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2027187.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with <i>ALK</i>-positive non–small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced <i>ALK</i>-positive NSCLC is unclear.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced <i>ALK</i>-positive NSCLC who had received no previous systemic treatment for metastatic disease. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included independently assessed objective response and intracranial response. An interim analysis of efficacy was planned after approximately 133 of 177 (75%) expected events of disease progression or death had occurred.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">The percentage of patients who were alive without disease progression at 12 months was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; P&lt;0.001). An objective response occurred in 76% (95% CI, 68 to 83) of the patients in the lorlatinib group and 58% (95% CI, 49 to 66) of those in the crizotinib group; among those with measurable brain metastases, 82% (95% CI, 57 to 96) and 23% (95% CI, 5 to 54), respectively, had an intracranial response, and 71% of the patients who received lorlatinib had an intracranial complete response. The most common adverse events with lorlatinib were hyperlipidemia, edema, increased weight, peripheral neuropathy, and cognitive effects. Lorlatinib was associated with more grade 3 or 4 adverse events (mainly altered lipid levels) than crizotinib (in 72% vs. 56%). Discontinuation of treatment because of adverse events occurred in 7% and 9% of the patients, respectively.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In an interim analysis of results among patients with previously untreated advanced <i>ALK</i>-positive NSCLC, those who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response than those who received crizotinib. The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of altered lipid levels. (Funded by Pfizer; CROWN ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03052608" target="_blank">NCT03052608</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo005883/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/d239d013-f857-4897-9ebe-bf096ffc9c9e/media/NEJMdo005883_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo005883/full/" class="ng-do-media_item-title-link">Lorlatinib versus Crizotinib in Advanced <i>ALK</i>-Positive Lung Cancer</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 3s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Chromosomal rearrangements involving the anaplastic lymphoma kinase (<i>ALK</i>) gene define a subset of non–small-cell lung cancers (NSCLCs) that are highly sensitive to small-molecule ALK tyrosine kinase inhibitors.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> One trial showed that the efficacy of the first-generation ALK inhibitor crizotinib as first-line therapy was superior to that of platinum–pemetrexed chemotherapy<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-1" href-manipulated="true" aria-label="Reference 3">3</a></sup>; this finding established crizotinib as a standard first-line treatment for advanced <i>ALK</i>-positive NSCLC. <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-d">Subsequently, several randomized, phase 3 studies showed that more potent second-generation ALK inhibitors, including alectinib, brigatinib, and ensartinib, were superior to crizotinib as first-line therapy<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r6 r7 r8" id="body-ref-r8-1" href-manipulated="true">4-8</a></sup>; these findings led to the adoption of second-generation inhibitors as standard first-line treatments.</span> However, despite the improved efficacy of second-generation inhibitors, drug resistance and recurrent disease<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10" id="body-ref-r10" href-manipulated="true">9,10</a></sup> — including central nervous system (CNS) progression, a major cause of illness and death — still develop.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13 r14 r15" id="body-ref-r15" href-manipulated="true">11-15</a></sup></div><div role="paragraph">Lorlatinib (Pfizer) is a novel third-generation ALK inhibitor that is more potent than second-generation inhibitors in biochemical and cellular assays and has the broadest coverage of <i>ALK</i> resistance mutations that have been identified.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r16 r17" id="body-ref-r17-1" href-manipulated="true">9,16,17</a></sup> Lorlatinib was designed to cross the blood–brain barrier in order to achieve high exposures in the CNS.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19" id="body-ref-r19-1" href-manipulated="true">18,19</a></sup> In phase 1 and 2 studies, lorlatinib had potent antitumor activity after the failure of previous ALK inhibitors (first-generation, second-generation, or both).<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20" id="body-ref-r20-1" href-manipulated="true">19,20</a></sup> In particular, lorlatinib had marked intracranial activity in previously treated patients with baseline CNS disease, including leptomeningeal disease.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r20" id="body-ref-r20-2" href-manipulated="true">11,12,20</a></sup> Because of its efficacy and safety, lorlatinib is a standard treatment option for <i>ALK</i>-positive patients in whom one or more ALK inhibitors have failed.</div><div role="paragraph">The CROWN trial is a global, randomized, phase 3 trial comparing lorlatinib with crizotinib (the standard-of-care first-line treatment at the time of trial initiation) in patients with previously untreated advanced <i>ALK</i>-positive NSCLC. Here, we report the results of a planned interim analysis of the CROWN trial.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">Eligible patients (≥18 or ≥20 years of age, according to local regulations) had histologically or cytologically confirmed locally advanced or metastatic NSCLC with <i>ALK</i> status determined by means of the Ventana ALK (D5F3) CDx immunohistochemical assay. No previous systemic treatment for metastatic disease was allowed. Patients with asymptomatic treated or untreated CNS metastases were eligible. Patients had to have at least one extracranial measurable target lesion (according to the Response Evaluation Criteria in Solid Tumours [RECIST], version 1.1) that had not been previously irradiated; an Eastern Cooperative Oncology Group performance-status score of 0 to 2 (on a 5-point scale in which higher numbers reflect greater disability); and adequate bone marrow, pancreatic, renal, and liver function (as defined in the trial <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org). All the patients provided written informed consent.</div></section><section id="sec-1-2"><h3>Trial Oversight</h3><div role="paragraph">The protocol and amendments were approved by the institutional review board or independent ethics committee at each site and complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and local laws. The trial was designed by the sponsor and members of the steering committee. Data were collected by the investigators and analyzed by the sponsor. The first author wrote the first draft of the manuscript. All the authors contributed to the interpretation of the data and to the development, writing, and approval of the manuscript. All the authors had full access to the raw data and vouch for the completeness and accuracy of the data reported and for the adherence of the trial to the protocol.</div></section><section id="sec-1-3"><h3>Trial Design and Treatment</h3><div role="paragraph">Patients were randomly assigned in a 1:1 ratio to receive either oral lorlatinib at a dose of 100 mg daily or oral crizotinib at a dose of 250 mg twice daily (with each drug to be taken either with or without food) in a course of treatment that was measured in cycles of 28 days. Randomization was stratified according to the presence of brain metastases (yes or no) and ethnic group (Asian or non-Asian). Per protocol, crossover between the treatment groups was not permitted.</div><div role="paragraph">The primary end point was progression-free survival, defined as the time from randomization to RECIST-defined disease progression (as determined by blinded independent central review) or death from any cause. Secondary end points included progression-free survival as assessed by the investigator, overall survival, objective response, objective intracranial response, and safety. Treatment continued until independently assessed RECIST-defined disease progression, death, withdrawal of consent, or unacceptable toxic effects. At the investigator’s discretion, patients were allowed to continue treatment after RECIST-defined progression.</div></section><section id="sec-1-4"><h3>Assessments</h3><div role="paragraph">Tumor assessments were performed at screening and then every 8 weeks (±1 week) starting from randomization until independently assessed RECIST-defined disease progression. Imaging assessments included chest, abdomen, and pelvis computed tomography (CT) or magnetic resonance imaging (MRI) and brain MRI. MRI of the CNS was required at baseline and at each tumor assessment, regardless of the patient’s baseline CNS status. The intracranial response was assessed by an independent committee using a modified version of RECIST, version 1.1.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup></div><div role="paragraph">Safety assessments included adverse events, vital signs, physical examination, 12-lead electrocardiography, echocardiography with multigated acquisition scanning, and laboratory assessments. Adverse events were classified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">An interim analysis was planned after approximately 75% (133) of 177 expected events of disease progression or death had been observed. Sample-size assumptions were a median duration of progression-free survival of 18 months in the lorlatinib group and 11 months in the crizotinib group, at least 90% power to detect a hazard ratio of 0.611 with a one-sided stratified log-rank test at a significance level of 0.025 (one-sided), and a two-look, group-sequential design with a Lan–DeMets alpha-spending function with O’Brien–Fleming boundaries to determine the efficacy boundaries. For this interim analysis, the primary end point of progression-free survival was tested at a one-sided alpha level of 0.0081 based on an updated boundary corresponding to the 72% information fraction observed at the interim analysis. The data cutoff date was March 20, 2020. Overall survival was to be hierarchically tested for significance at the time of the interim or final analysis of progression-free survival, provided that the primary end point was statistically significant, favoring the lorlatinib group.</div><div role="paragraph">Efficacy end points were measured in the intention-to-treat population, which included all the patients who had undergone randomization. The Kaplan–Meier method was used to estimate time-to-event end points. One-sided log-rank tests, stratified according to baseline factors, were used for between-group comparisons of progression-free survival and overall survival; stratified Cox regression models were applied to estimate hazard ratios. A one-sided stratified Cochran–Mantel–Haenszel test was used to compare the between-group difference in response. Safety evaluations were performed in the as-treated population, which included all the patients who had received at least one dose of lorlatinib or crizotinib. Safety results were not adjusted for the shorter duration of treatment in the crizotinib group.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">From May 2017 through February 2019, a total of 296 patients at 104 centers in 23 countries underwent randomization (149 to receive lorlatinib and 147 to receive crizotinib). Five patients in the crizotinib group did not receive treatment but were included in the intention-to-treat population (<a href="#f1">Figure 1</a>). Baseline demographic and disease characteristics were well balanced in the treatment groups (<a href="#t1">Table 1</a>). CNS metastases at baseline, as assessed by blinded independent central review, were present in 38 patients (26%) in the lorlatinib group and 40 patients (27%) in the crizotinib group. At the time of data cutoff, 103 patients in the lorlatinib group and 31 patients in the crizotinib group were continuing to receive the assigned treatment. The median duration of follow-up for progression-free survival was 18.3 months in the lorlatinib group and 14.8 months in the crizotinib group.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f1.jpg"><img src="/cms/10.1056/NEJMoa2027187/asset/36201cc3-90d7-4f2c-af4e-53d9075534ee/assets/images/large/nejmoa2027187_f1.jpg" height="3097" width="2231" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Randomization, Treatment, and Follow-up.</div><div class="notes"><div role="doc-footnote">A total of 296 patients were randomly assigned to receive either lorlatinib or crizotinib. The intention-to-treat population included all the patients who underwent randomization. The as-treated population included all the patients who received at least one dose of lorlatinib or crizotinib.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t1.jpg"><img src="/cms/10.1056/NEJMoa2027187/asset/1b228182-ad15-4280-8b26-572caf533e13/assets/images/large/nejmoa2027187_t1.jpg" height="2721" width="1136" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Lorlatinib<br>(N=149)</th><th class="txxr-borders">Crizotinib<br>(N=147)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age — yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">59.1±13.1</td><td class="xxxr-borders">55.6±13.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">61</td><td class="xxxr-borders shading">56</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Interquartile range</td><td class="xxxx-borders">51–69</td><td class="xxxr-borders">45–66</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Sex — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">84 (56)</td><td class="xxxr-borders">91 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">65 (44)</td><td class="xxxr-borders shading">56 (38)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Race or ethnic group — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">72 (48)</td><td class="xxxr-borders shading">72 (49)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">65 (44)</td><td class="xxxr-borders">65 (44)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Missing</td><td class="xxxx-borders">12 (8)</td><td class="xxxr-borders">9 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance-status score — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">67 (45)</td><td class="xxxr-borders">57 (39)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">79 (53)</td><td class="xxxr-borders shading">81 (55)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">9 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Smoking status — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Never smoked</td><td class="xxxx-borders">81 (54)</td><td class="xxxr-borders">94 (64)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Previous smoker</td><td class="xxxx-borders shading">55 (37)</td><td class="xxxr-borders shading">43 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Current smoker</td><td class="xxxx-borders">13 (9)</td><td class="xxxr-borders">9 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Current stage of disease — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">IIIA</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">IIIB</td><td class="xxxx-borders shading">12 (8)</td><td class="xxxr-borders shading">8 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">IV</td><td class="xxxx-borders">135 (91)</td><td class="xxxr-borders">139 (95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Histologic type — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adenocarcinoma</td><td class="xxxx-borders shading">140 (94)</td><td class="xxxr-borders shading">140 (95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adenosquamous carcinoma</td><td class="xxxx-borders">6 (4)</td><td class="xxxr-borders">5 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Large-cell carcinoma</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Squamous-cell carcinoma</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Use of previous anticancer drug therapy — no. (%)<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">12 (8)</td><td class="xxxr-borders shading">9 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Previous brain radiotherapy — no. (%)</td><td class="xxxx-borders">9 (6)</td><td class="xxxr-borders">10 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Brain metastases at baseline — no. (%)</td><td class="xbxx-borders shading">38 (26)</td><td class="xbxr-borders shading">40 (27)</td></tr></tbody></table></div><figcaption><div class="caption">Baseline Patient Characteristics in the Intention-to-Treat Population.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race or ethnic group was reported by the investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5, with higher scores indicating greater disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Smoking status was not reported for one patient in the crizotinib group.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">The disease stage in one patient who had locally advanced disease at trial entry was defined according to the American Joint Committee on Cancer (AJCC), version 8.0, instead of AJCC, version 7.0, as required by the protocol. This stage was therefore classified as “other.”</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">According to the protocol, previous adjuvant or neoadjuvant anticancer therapy was allowed if it had been completed more than 12 months before randomization. One patient who had received previous chemotherapy for metastatic disease was reported as having a protocol violation.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph">Among the 296 patients in the intention-to-treat population, 127 had had disease progression or died by the time of the data cutoff (41 of 149 patients [28%] in the lorlatinib group and 86 of 147 patients [59%] in the crizotinib group). <a id="exam-tint-one-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-d">The percentage of patients who were alive without disease progression at 12 months was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio, 0.28; 95% CI, 0.19 to 0.41; P&lt;0.001)</span> (<a href="#f2">Figure 2A</a>). The hazard ratio favored lorlatinib over crizotinib across all prespecified patient subgroups defined according to baseline characteristics and stratification factors (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). Progression-free survival as assessed by the investigators was also significantly longer with lorlatinib than with crizotinib; the percentages of patients with progression-free survival at 12 months were 80% (95% CI, 73 to 86) and 35% (95% CI, 27 to 43), respectively (hazard ratio 0.21; 95% CI, 0.14 to 0.31) (Fig. S2).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f2.jpg"><img src="/cms/10.1056/NEJMoa2027187/asset/19964ad5-4b64-455b-8a1f-7888ee796a58/assets/images/large/nejmoa2027187_f2.jpg" height="3374" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Efficacy Outcomes in the Intention-to-Treat Population.</div><div class="notes"><div role="doc-footnote">Panel A shows Kaplan–Meier estimates of progression-free survival, according to blinded independent central review (BICR) in the intention-to-treat population. Progression-free survival was significantly longer with lorlatinib than crizotinib; the median progression-free survival with lorlatinib was not reached. Tick marks on the survival curves indicate censoring of data. NR denotes not reached. Panel B shows Kaplan–Meier estimates of time to intracranial progression, as assessed by BICR, in the intention-to-treat population. Time to intracranial progression was defined as the time from randomization to the first objective progression of central nervous system (CNS) disease (either new brain metastases or progression of existing brain metastases). Panel C shows the cumulative incidence of CNS progression as the first event, as assessed by BICR in the intention-to-treat population. Cumulative-incidence probabilities were calculated with the use of a competing-risks approach, with values adjusted for the competing risks of non-CNS progression and death (Fig. S3 in the <a href="#ap2">Supplementary Appendix</a>). Panel D shows Kaplan–Meier curves of overall survival.</div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-one-c"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-c">The percentage of patients with a confirmed objective response as assessed by blinded independent central review was significantly higher with lorlatinib than with crizotinib (76% [95% CI, 68 to 83] vs. 58% [95% CI, 49 to 66])</span> (<a href="#t2">Table 2</a>). A total of 70% of the patients who received lorlatinib and 27% of those who received crizotinib had a response that lasted at least 12 months. Similar responses (both the percentage of patients with a confirmed objective response and the percentage of patients with a response lasting ≥12 months) were determined by investigator assessment (Table S1).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t2.jpg"><img src="/cms/10.1056/NEJMoa2027187/asset/7890bf10-33f5-4f07-8514-c225a385f3fc/assets/images/large/nejmoa2027187_t2.jpg" height="2195" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Lorlatinib</th><th class="txxx-borders">Crizotinib</th><th class="txxr-borders">Odds Ratio<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Intention-to-treat population</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">149</td><td class="xxxx-borders">147</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Confirmed objective response</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients</td><td class="xxxx-borders">113</td><td class="xxxx-borders">85</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">% (95% CI)</td><td class="xxxx-borders shading">76 (68–83)</td><td class="xxxx-borders shading">58 (49–66)</td><td class="xxxr-borders shading">2.25 (1.35–3.89)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response — no. (%)</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response — no. (%)</td><td class="xxxx-borders shading">109 (73)</td><td class="xxxx-borders shading">85 (58)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Stable disease — no. (%)</td><td class="xxxx-borders">19 (13)</td><td class="xxxx-borders">41 (28)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Neither complete response nor progressive disease — no. (%)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Progressive disease — no. (%)</td><td class="xxxx-borders">10 (7)</td><td class="xxxx-borders">7 (5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Could not be evaluated — no. (%)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">NE (NE–NE)</td><td class="xxxx-borders">11.0 (9.0–12.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time to tumor response (IQR) — mo</td><td class="xxxx-borders shading">1.8 (1.7–1.9)</td><td class="xxxx-borders shading">1.8 (1.7–1.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Patients with measurable or nonmeasurable brain metastases at</b> <b>baseline</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">38</td><td class="xxxx-borders shading">40</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Confirmed CNS response</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">25</td><td class="xxxx-borders shading">8</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">% (95% CI)</td><td class="xxxx-borders">66 (49–80)</td><td class="xxxx-borders">20 (9–36)</td><td class="xxxr-borders">8.41 (2.59–27.23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CNS complete response — no. (%)</td><td class="xxxx-borders shading">23 (61)</td><td class="xxxx-borders shading">6 (15)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">NE (NE–NE)</td><td class="xxxx-borders">9.4 (6.0–11.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time to tumor response (IQR) — mo</td><td class="xxxx-borders shading">1.9 (1.8–3.7)</td><td class="xxxx-borders shading">1.8 (1.7–2.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Patients with measurable brain metastases at</b> <b>baseline</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">13</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Confirmed CNS response</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">% (95% CI)</td><td class="xxxx-borders">82 (57–96)</td><td class="xxxx-borders">23 (5–54)</td><td class="xxxr-borders">16.83 (1.95–163.23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CNS complete response — no. (%)</td><td class="xxxx-borders shading">12 (71)</td><td class="xxxx-borders shading">1 (8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">NE (NE–NE)</td><td class="xxxx-borders">10.2 (9.4–11.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Median time to tumor response (IQR) — mo</td><td class="xbxx-borders shading">1.9 (1.8–3.5)</td><td class="xbxx-borders shading">1.9 (1.8–1.9)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Objective Response in the Intention-to-Treat Population and among Patients with Brain Metastases at Baseline.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Responses in patients with brain metastases at baseline were assessed by blinded independent central review. An odds ratio greater than 1 indicates a better outcome with lorlatinib than with crizotinib. CI denotes confidence interval, CNS central nervous system, IQR interquartile range, and NE could not be evaluated.</div></div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-one-b"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="one-b">Among the 78 patients with measurable or nonmeasurable CNS metastases at baseline, the percentage of those with a confirmed objective intracranial response as assessed by blinded independent central review was significantly higher with lorlatinib than with crizotinib (66% [95% CI, 49 to 80] vs. 20% [95% CI, 9 to 36]); 61% and 15%, respectively, had a complete intracranial response (<a href="#t2">Table 2</a>). The percentage of patients with a duration of intracranial response of at least 12 months was 72% with lorlatinib and 0% with crizotinib. Among the 30 patients with measurable CNS metastases at baseline, 82% (95% CI, 57 to 96) in the lorlatinib group and 23% (95% CI, 5 to 54) in the crizotinib group had an intracranial response, and 71% and 8%, respectively, had a complete response</span> (<a href="#t2">Table 2</a>).</div><div role="paragraph">In the intention-to-treat population, the time to CNS progression was significantly longer with lorlatinib than with crizotinib. The percentage of patients who were alive without CNS progression at 12 months was 96% (95% CI, 91 to 98) with lorlatinib and 60% (95% CI, 49 to 69) with crizotinib (hazard ratio, 0.07; 95% CI, 0.03 to 0.17) (<a href="#f2">Figure 2B</a>). The cumulative incidence of CNS progression as the first event, with adjustment for the competing risks of non-CNS progression and death, was significantly lower in the lorlatinib group than in the crizotinib group. At 12 months, the cumulative incidence of CNS progression as the first event was 3% with lorlatinib and 33% with crizotinib (hazard ratio, 0.06; 95% CI, 0.02 to 0.18) (<a href="#f2">Figure 2C</a>).</div><div role="paragraph"><a id="exam-tint-one-a"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="one-a">At the time of data cutoff, overall survival data were still evolving, with deaths occurring in a total of 51 patients in the intention-to-treat population (23 patients [15%] in the lorlatinib group and 28 patients [19%] in the crizotinib group). The hazard ratio for death was 0.72 (95% CI, 0.41 to 1.25); the between-group difference in overall survival was not significant</span> (<a href="#f2">Figure 2D</a>).</div></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph">In total, 291 of 296 patients received at least one dose of lorlatinib or crizotinib. The percentage of patients who continued to receive trial treatment for at least 12 months was 76% (113 of 149) in the lorlatinib group and 35% (49 of 142) in the crizotinib group, with 69% and 22% of the patients, respectively, still receiving treatment at the time of the data cutoff. <a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">Adverse events of any grade that occurred more frequently (by more than 10 percentage points) with lorlatinib than with crizotinib included hypercholesterolemia (occurring in 70% of the patients vs. 4%), hypertriglyceridemia (in 64% vs. 6%), edema (55% vs. 39%), increased weight (38% vs. 13%), peripheral neuropathy (34% vs. 15%), cognitive effects (21% vs. 6%), anemia (19% vs. 8%), hypertension (18% vs. 2%), mood effects (16% vs. 5%), and hyperlipidemia (11% vs. 0%). Consistent with previous studies of lorlatinib, changes in cognition (including memory impairment, disturbance in attention, and amnesia) and mood (including anxiety, depression, and affect lability) were typically grade 1 and reversible with dose interruption.</span><sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20 r22 r23" id="body-ref-r23-1" href-manipulated="true">19,20,22,23</a></sup></div><div role="paragraph">Adverse events that were more common with crizotinib than with lorlatinib included diarrhea (occurring in 52% of the patients vs. 21%), nausea (in 52% vs. 15%), vision disorder (39% vs. 18%), vomiting (39% vs. 13%), increased alanine aminotransferase level (34% vs. 17%), fatigue (32% vs. 19%), constipation (30% vs. 17%), increased aspartate aminotransferase level (27% vs. 14%), decreased appetite (25% vs. 3%), dysgeusia (16% vs. 5%), and bradycardia (12% vs. 1%) (<a href="#t3">Table 3</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t3.jpg"><img src="/cms/10.1056/NEJMoa2027187/asset/a7327bf9-ad16-42ce-94ca-c56b099c8fb0/assets/images/large/nejmoa2027187_t3.jpg" height="2013" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><td class="txlx-borders">&nbsp;</td><th class="txxx-borders" colspan="5"><span>Lorlatinib (N=149)</span></th><th class="txxr-borders" colspan="5"><span>Crizotinib (N=142)</span></th></tr><tr class="head2" data-type="row head2"><th class="xxlx-borders" data-xml-align="left">Event</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 1</th><th class="xxxx-borders">Grade 2</th><th class="xxxx-borders">Grade 3</th><th class="xxxx-borders">Grade 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 1</th><th class="xxxx-borders">Grade 2</th><th class="xxxx-borders">Grade 3</th><th class="xxxr-borders">Grade 4</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="10"><span><i>number of patients (percent)</i></span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">149 (100)</td><td class="xxxx-borders shading">6 (4)</td><td class="xxxx-borders shading">28 (19)</td><td class="xxxx-borders shading">87 (58)</td><td class="xxxx-borders shading">21 (14)</td><td class="xxxx-borders shading">140 (99)</td><td class="xxxx-borders shading">8 (6)</td><td class="xxxx-borders shading">46 (32)</td><td class="xxxx-borders shading">67 (47)</td><td class="xxxr-borders shading">12 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hypercholesterolemia<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">105 (70)</td><td class="xxxx-borders">24 (16)</td><td class="xxxx-borders">57 (38)</td><td class="xxxx-borders">23 (15)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">5 (4)</td><td class="xxxx-borders">5 (4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertriglyceridemia<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">95 (64)</td><td class="xxxx-borders shading">28 (19)</td><td class="xxxx-borders shading">37 (25)</td><td class="xxxx-borders shading">19 (13)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxx-borders shading">8 (6)</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Edema<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">82 (55)</td><td class="xxxx-borders">54 (36)</td><td class="xxxx-borders">22 (15)</td><td class="xxxx-borders">6 (4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">56 (39)</td><td class="xxxx-borders">38 (27)</td><td class="xxxx-borders">16 (11)</td><td class="xxxx-borders">2 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Increased weight</td><td class="xxxx-borders shading">57 (38)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxx-borders shading">21 (14)</td><td class="xxxx-borders shading">25 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">18 (13)</td><td class="xxxx-borders shading">6 (4)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Peripheral neuropathy<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">50 (34)</td><td class="xxxx-borders">36 (24)</td><td class="xxxx-borders">11 (7)</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">21 (15)</td><td class="xxxx-borders">19 (13)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Cognitive effects<a href="#t3fn2" role="doc-noteref">†</a><a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">32 (21)</td><td class="xxxx-borders shading">20 (13)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (6)</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">32 (21)</td><td class="xxxx-borders">21 (14)</td><td class="xxxx-borders">9 (6)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">74 (52)</td><td class="xxxx-borders">67 (47)</td><td class="xxxx-borders">6 (4)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">29 (19)</td><td class="xxxx-borders shading">16 (11)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">11 (8)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">29 (19)</td><td class="xxxx-borders">25 (17)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">46 (32)</td><td class="xxxx-borders">25 (18)</td><td class="xxxx-borders">17 (12)</td><td class="xxxx-borders">4 (3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">27 (18)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxx-borders shading">15 (10)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Vision disorder<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">27 (18)</td><td class="xxxx-borders">25 (17)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">56 (39)</td><td class="xxxx-borders">54 (38)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Increased ALT level</td><td class="xxxx-borders shading">26 (17)</td><td class="xxxx-borders shading">22 (15)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">48 (34)</td><td class="xxxx-borders shading">26 (18)</td><td class="xxxx-borders shading">16 (11)</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Constipation</td><td class="xxxx-borders">26 (17)</td><td class="xxxx-borders">24 (16)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">42 (30)</td><td class="xxxx-borders">30 (21)</td><td class="xxxx-borders">11 (8)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Mood effects<a href="#t3fn2" role="doc-noteref">†</a><a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">24 (16)</td><td class="xxxx-borders shading">14 (9)</td><td class="xxxx-borders shading">8 (5)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">22 (15)</td><td class="xxxx-borders">21 (14)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">74 (52)</td><td class="xxxx-borders">56 (39)</td><td class="xxxx-borders">15 (11)</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Increased AST level</td><td class="xxxx-borders shading">21 (14)</td><td class="xxxx-borders shading">18 (12)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">39 (27)</td><td class="xxxx-borders shading">30 (21)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Vomiting</td><td class="xxxx-borders">19 (13)</td><td class="xxxx-borders">16 (11)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">55 (39)</td><td class="xxxx-borders">42 (30)</td><td class="xxxx-borders">11 (8)</td><td class="xxxx-borders">2 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hyperlipidemia</td><td class="xxxx-borders shading">16 (11)</td><td class="xxxx-borders shading">6 (4)</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Dysgeusia</td><td class="xxxx-borders">8 (5)</td><td class="xxxx-borders">8 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">23 (16)</td><td class="xxxx-borders">20 (14)</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">35 (25)</td><td class="xxxx-borders shading">23 (16)</td><td class="xxxx-borders shading">8 (6)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Bradycardia</td><td class="xbxx-borders">2 (1)</td><td class="xbxx-borders">2 (1)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">17 (12)</td><td class="xbxx-borders">15 (11)</td><td class="xbxx-borders">2 (1)</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events in the Safety Population.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Shown are adverse events that differed by more than 10 percentage points in frequency between the groups. Patients were counted only once per event. The listed events occurred after the first dose of trial treatment through the end of trial follow-up or the start of new anticancer therapy, whichever took place first. Data for all grades in the lorlatinib group are listed in decreasing order of frequency. ALT denotes alanine aminotransferase, and AST aspartate aminotransferase.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">This category comprised a cluster of adverse events that may represent similar clinical symptoms or syndromes.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">Cognitive effects with a frequency of at least 1% included memory impairment, disturbance in attention, confusion, amnesia, cognitive disorder, and delirium.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">Mood effects with a frequency of at least 1% included anxiety, depression, affect lability, affective disorder, agitation, irritability, and altered mood.</div></div></div></figcaption></figure></div><div role="paragraph">Grade 3 or 4 adverse events occurred in 72% of the patients who received lorlatinib and 56% of those who received crizotinib (<a href="#t3">Table 3</a> and Table S2). The most common grade 3–4 adverse events in the lorlatinib group were elevated triglyceride levels (20%), increased weight (17%), elevated cholesterol levels (16%), and hypertension (10%). The most common grade 3–4 adverse events in the crizotinib group were laboratory abnormalities. Serious adverse events occurred in 34% of the patients in the lorlatinib group and 27% of those in the crizotinib group (Table S3). Fatal adverse events occurred in 14 patients (7 [5%] in the lorlatinib group and 7 [5%] in the crizotinib group) (Table S4).</div><div role="paragraph">Adverse events leading to dose interruption or dose reduction, respectively, were reported in 49% and 21% of the patients in the lorlatinib group and in 47% and 15% of those in the crizotinib group (data on dose reductions are provided in Table S5). Adverse events leading to treatment discontinuation occurred in 7% of the patients who received lorlatinib and in 9% of those who received crizotinib (Table S6).</div></section><section id="sec-2-4"><h3>Patient-Reported Outcomes</h3><div role="paragraph">Mean (±SE) baseline scores in measures of global quality of life were 64.6±1.82 in the lorlatinib group and 59.8±1.90 in the crizotinib group. Patients in the lorlatinib group had a significantly greater overall improvement from baseline in global quality of life than those who received crizotinib (estimated mean difference, 4.65; 95% CI, 1.14 to 8.16), although the difference was not clinically meaningful (Fig. S4A). Improvements in quality of life were seen as early as cycle 2 and were maintained over time in the lorlatinib group (Fig. S4B).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In this interim analysis of a randomized, phase 3 trial, we compared the third-generation ALK inhibitor lorlatinib with the first-generation inhibitor crizotinib in patients with previously untreated advanced <i>ALK</i>-positive NSCLC. <a id="exam-tint-three-c"></a><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="three-c">Although crizotinib was the standard first-line therapy for advanced <i>ALK</i>-positive NSCLC<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-2" href-manipulated="true" aria-label="Reference 3">3</a></sup> when the CROWN trial was initiated in 2017, it has now been supplanted by more potent second-generation ALK inhibitors.</span><sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r24" id="body-ref-r24" href-manipulated="true">4,5,24</a></sup> In the global ALEX trial, alectinib was shown to be superior to crizotinib as first-line therapy, with a median duration of progression-free survival of 25.7 months versus 10.4 months, respectively (hazard ratio, 0.50), as assessed by an independent review committee.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-3" href-manipulated="true" aria-label="Reference 4">4</a></sup> Similarly, at the second interim analysis of the ALTA-1L (ALK in Lung Cancer Trial of Brigatinib in 1st Line) trial, progression-free survival was significantly longer among patients who received brigatinib than among those who received crizotinib, with median duration of progression-free survival of 24 months and a hazard ratio for disease progression or death of 0.49.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-2" href-manipulated="true" aria-label="Reference 8">8</a></sup> Most recently, in the eXalt3 trial, ensartinib was also shown to be superior to crizotinib, with a median duration of progression-free survival of 25.8 months and a hazard ratio for disease progression or death of 0.51.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6-2" href-manipulated="true" aria-label="Reference 6">6</a></sup></div><div role="paragraph">In the CROWN trial, progression-free survival was significantly longer among patients with <i>ALK</i>-positive NSCLC who received first-line lorlatinib than among those who received crizotinib. Although the length of follow-up does not allow determination of the median duration of progression-free survival, the hazard ratio for disease progression or death was 0.28, as assessed by blinded independent central review, which corresponds to a 72% lower risk of progression or death with lorlatinib than with crizotinib. Cross-trial comparisons are inherently limited because of differences in trial designs and trial populations; however, the magnitude of benefit, relative to crizotinib, appears to be at least as large for lorlatinib as for other second-generation inhibitors, all of which have been associated with an approximately 50% lower risk of progression or death than crizotinib.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r6" id="body-ref-r6-3" href-manipulated="true">4-6</a></sup> The efficacy observed in the crizotinib group in the CROWN trial was similar to that observed in the crizotinib control groups in other randomized studies of next-generation inhibitors, and the median duration of follow-up in the CROWN trial was similar to that reported in the primary analysis of the global ALEX trial.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-5" href-manipulated="true" aria-label="Reference 4">4</a></sup></div><div role="paragraph">Several factors may underlie the marked efficacy of lorlatinib as first-line therapy. First, multiple preclinical studies have shown that lorlatinib is more potent in inhibiting ALK than first- or second-generation inhibitors.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r16 r17" id="body-ref-r17-2" href-manipulated="true">9,16,17</a></sup> In addition, lorlatinib retains potency against all known single <i>ALK</i> resistance mutations, including <i>ALK</i> G1202R, which was the most common secondary <i>ALK</i> mutation identified after disease progression in patients who were receiving second-generation inhibitors.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r17" id="body-ref-r17-3" href-manipulated="true">9,17</a></sup> Consistent with the preclinical findings, lorlatinib has had marked clinical activity in patients with tumors that progressed while they were receiving first-generation inhibitors, second-generation inhibitors, or both, with greater efficacy noted among patients with secondary <i>ALK</i> resistance mutations.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20 r25" id="body-ref-r25" href-manipulated="true">20,25</a></sup> In untreated patients, lorlatinib may eliminate rare preexisting subclones harboring <i>ALK</i> resistance mutations or prevent the emergence of such resistant subclones.</div><div role="paragraph">Second, lorlatinib was designed to be CNS penetrant and has been shown in preclinical and clinical studies to be highly effective in treating CNS metastases.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r19" id="body-ref-r19-4" href-manipulated="true">16,19</a></sup> In a phase 2 study of lorlatinib, among patients previously treated with a second-generation inhibitor such as alectinib or brigatinib, both of which are highly CNS active, the confirmed intracranial response with lorlatinib was 53 to 56%, with a median duration of intracranial response ranging from 14.5 months to not reached.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20-5" href-manipulated="true" aria-label="Reference 20">20</a></sup> Among patients previously treated with crizotinib, which has poor brain penetrance,<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> the confirmed intracranial response was even higher, at 87%.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20-6" href-manipulated="true" aria-label="Reference 20">20</a></sup> The marked intracranial activity of lorlatinib after failure of first-generation ALK inhibitors, second-generation ALK inhibitors, or both suggests that as first-line therapy, lorlatinib may be particularly effective in treating and preventing brain metastases. In the CROWN trial, the intracranial response among patients with measurable brain metastases at baseline was 82%, with a complete intracranial response of 71%. In the global ALEX, ALTA-1L, and eXalt3 trials, the corresponding complete intracranial responses with alectinib, brigatinib, and ensartinib were 38%, 28%, and 27%, respectively.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r6 r8" id="body-ref-r8-3" href-manipulated="true">4,6,8</a></sup> In addition, in the CROWN trial, lorlatinib significantly decreased the cumulative incidence of CNS progression, which suggests that the prolonged progression-free survival seen with lorlatinib may be due in part to the prevention of CNS metastases.</div><div role="paragraph">Overall, the safety profile of lorlatinib was similar to that reported in previous studies.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20 r27" id="body-ref-r27" href-manipulated="true">19,20,27</a></sup> Lorlatinib has a distinct side-effect profile as compared with other ALK inhibitors. In the patients who received lorlatinib, cognitive effects were reported in 21% and mood side effects were reported in 16%, and these side effects were predominantly low grade. As reported previously, cognitive and mood changes typically present within the first 2 months after lorlatinib administration and are managed with dose interruption and reduction.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20 r22 r23" id="body-ref-r23-2" href-manipulated="true">19,20,22,23</a></sup> Weight gain, which was commonly reported in patients who received lorlatinib, may be associated with increased appetite.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22-3" href-manipulated="true" aria-label="Reference 22">22</a></sup> Both weight gain and cognitive and mood changes may be due to off-target inhibition of tropomyosin receptor kinase B in the CNS.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r28" id="body-ref-r28" href-manipulated="true">18,28</a></sup> Grade 3 or 4 adverse events were more frequent with lorlatinib than with crizotinib (in 72% vs. 56%). However, more than one half of the grade 3 or 4 adverse events in the lorlatinib group were elevated levels of cholesterol, triglycerides, or both. Hypercholesterolemia and hypertriglyceridemia, the most common adverse reactions reported with lorlatinib, are usually asymptomatic and readily managed with lipid-lowering agents and dose modifications as needed (details are provided in the Management of Hyperlipidemia section in the <a href="#ap2">Supplementary Appendix</a>).<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22 r23" id="body-ref-r23-3" href-manipulated="true">22,23</a></sup> Brigatinib was associated with a similarly higher incidence of adverse events of grade 3 or higher than crizotinib (73% vs. 61%),<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-4" href-manipulated="true" aria-label="Reference 8">8</a></sup> whereas alectinib showed a slightly lower incidence of grade 3 or higher adverse events than crizotinib (45% vs. 51%).<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-2" href-manipulated="true" aria-label="Reference 7">7</a></sup> Despite the higher incidence of grade 3 or 4 adverse events with lorlatinib, the discontinuations of treatment because of adverse events were similar in the two groups (in 7% of the patients who received lorlatinib and 9% of those who received crizotinib). Patient-reported outcomes also supported the safety and favorable side-effect profile of lorlatinib relative to crizotinib, and patients who received lorlatinib reported a significantly greater improvement in global quality of life than those who received crizotinib.</div><div role="paragraph">Among patients with previously untreated, advanced <i>ALK</i>-positive NSCLC, those who received lorlatinib had significantly longer progression-free survival, a higher overall and intracranial response, and better quality of life than those who received crizotinib. The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of hyperlipidemia, a known side effect of lorlatinib.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Pfizer</span>.</div><div role="paragraph">Dr. Shaw reports receiving advisory board fees and lecture fees from Blueprint Medicines and Foundation Medicine, advisory board fees from KSQ Therapeutics, grant support, paid to her institution, and consulting fees from Loxo Oncology and Turning Point Therapeutics, consulting fees from Bayer, Natera, Takeda, EMD Serono, Syros Pharmaceuticals, Chugai Pharmaceutical, Achilles Therapeutics, and ArcherDX, grant support, paid to her institution, consulting fees, and lecture fees from Ignyta, grant support, paid to her institution, and advisory board fees from ARIAD Pharmaceuticals, lecture fees from Guardant Health, consulting fees, lecture fees, and advisory board fees from Servier, grant support, paid to her institution, consulting fees, lecture fees, and advisory board fees from Genentech–Roche, and receiving grant support, being employed by, and owning stock in Novartis; Dr. Bauer, receiving grant support, paid to his institution, from Daiichi Sankyo, MedPacto, Incyte, Mirati Therapeutics, MedImmune, AbbVie, AstraZeneca, MabVax Therapeutics, Stemline Therapeutics, Merck, GlaxoSmithKline, Novartis, Genentech, Deciphera Pharmaceuticals, Merrimack Pharmaceuticals, ImmunoGen, Millennium Pharmaceuticals, Phosplatin Therapeutics, Calithera Biosciences, Kolltan Pharmaceuticals, Principia Biopharma, Peloton Therapeutics, Immunocore, Roche, Aileron Therapeutics, Amgen, Onyx Pharmaceuticals, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio Pharmaceuticals, TopAlliance Biosciences, Janssen Pharmaceutica, Clovis Oncology, Takeda, Karyopharm Therapeutics, and ARMO BioSciences, grant support, paid to his institution, consulting fees, fees for serving on a speakers bureau, and travel support from Eli Lilly and Bayer, grant support, paid to his institution, consulting fees, and travel support from Bristol Myers Squibb, Foundation Medicine, and Loxo Oncology, grant support and consulting fees, paid to his institution, from Leap Therapeutics, grant support and consulting fees, paid to his institution, and travel support from Ignyta and Moderna Therapeutics, grant support and consulting fees, paid to his institution, and consulting fees from Pfizer, consulting fees and travel support from Guardant Health, and consulting fees from Exelixis and Blueprint Medicines; Dr. de Marinis, receiving consulting fees and fees for serving on a speakers bureau from AstraZeneca, Bristol Myers Squibb, Roche–Genentech, Pfizer, and Merck Sharp &amp; Dohme; Dr. Felip, receiving advisory board fees from AbbVie, Blueprint Medicines, Guardant Health, Janssen Pharmaceutica, Merck, Samsung Biologics, GlaxoSmithKline, and Bayer, advisory board fees and fees for serving on a speakers bureau from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck Sharp &amp; Dohme, Novartis, Pfizer, Roche, and Takeda, fees for serving on a speakers bureau from Medscape, prIME Oncology, and Touch Independent Medical Education, grant support from Grant for Oncology Innovation and Fundación Merck Salud, and serving as a board member for Grifols; Dr. Goto, receiving grant support, lecture fees, and advisory board fees from Eli Lilly, Taiho Pharmaceutical, Pfizer, Novartis, Merck Sharp &amp; Dohme, Ono Pharmaceutical, Kyorin Pharmaceutical, and Bristol Myers Squibb, lecture fees and advisory board fees from Chugai Pharmaceutical, Boehringer Ingelheim, and AstraZeneca, grant support and advisory board fees from Guardant Health and Daiichi Sankyo, and advisory board fees from Illumina; Dr. Liu, receiving advisory board fees from Novartis, Bristol Myers Squibb, and Roche, grant support, advisory board fees, and honoraria from AstraZeneca and Takeda, advisory board fees and honoraria from Roche, and grant support from Boehringer Ingelheim; Dr. Mazieres, receiving grant support, advisory board fees, and lecture fees from Roche, AstraZeneca, Pierre Fabre, and Bristol Myers Squibb, advisory board fees and lecture fees from Merck Sharp &amp; Dohme, and advisory board fees from Daiichi Sankyo, Blueprint Medicines, Hengrui Therapeutics, and Pfizer; Dr. Kim, receiving travel support from Daiichi Sankyo and Amgen; Dr. Mok, receiving grant support, paid to his institution, lecture fees, consulting fees, advisory board fees, and fees for serving on a board of directors for AstraZeneca, lecture fees, consulting fees, and advisory board fees from Boehringer Ingelheim, Eli Lilly, Fishawack Facilitate, OrigiMed, and Daiichi Sankyo, fees for serving on a board of directors and being a shareholder in Hutchison China MediTech and Sanomics, fees for serving on a board of directors for the American Society of Clinical Oncology, fees for serving on a steering committee from the Chinese Society of Clinical Oncology, grant support, paid to his institution, lecture fees, consulting fees, and advisory board fees from Roche–Genentech, Pfizer, Merck Serono, Merck Sharp &amp; Dohme, Novartis, Bristol Myers Squibb, Takeda, and Clovis Oncology, grant support, paid to his institution, consulting fees, and advisory board fees from SFJ Pharmaceuticals, consulting fees and advisory board fees from Vertex Pharmaceuticals, Janssen Pharmaceutica, Incyte, OncoGenex Pharmaceuticals, Celgene, Ignyta, Cirina, Hengrui Therapeutics, Sanofi-Aventis R&amp;D, Yuhan, Loxo Oncology, ACEA Pharma, Alpha Biopharma, CStone Pharmaceuticals, IQVIA, Virtus Medical Group, Biolidics, Bayer, Lunit, Mirati Therapeutics, Gritstone Oncology, Guardant Health, and Blueprint Medicines, serving as a consultant for GeneDecode, grant support, paid to his institution, from Xcovery, and G1 Therapeutics, lecture fees from prIME Oncology, Amoy Diagnostics, InMed Medical Communication, Medscape–WebMD, PeerVoice, MDHealth Brazil, and P. Permanyer, and consulting fees from MORE Health; Ms. Polli and Drs. Thurm, Calella, and Peltz, being employed by and owning stock in Pfizer; and Dr. Solomon, receiving advisory board fees and lecture fees from Roche–Genentech, Novartis, AstraZeneca, Merck, and Bristol Myers Squibb and advisory board fees from Amgen, Eli Lilly, Loxo Oncology, PharmaMar, and Pfizer. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the participating patients and their families, as well as the research nurses, trial coordinators, and operations staff; Laura Iadeluca, Ph.D., of Pfizer, for the analysis of the patient-reported outcomes; and Paul O’Neill, Ph.D., of CMC AFFINITY, McCann Health Medical Communications, for editorial support with an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2027187_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2027187/suppl_file/nejmoa2027187_protocol.pdf" download="nejmoa2027187_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2027187_protocol.pdf" data-doi="10.1056/NEJMoa2027187">Download</a></li><li>5.42 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2027187_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2027187/suppl_file/nejmoa2027187_appendix.pdf" download="nejmoa2027187_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2027187_appendix.pdf" data-doi="10.1056/NEJMoa2027187">Download</a></li><li>769.30 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2027187_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2027187/suppl_file/nejmoa2027187_disclosures.pdf" download="nejmoa2027187_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2027187_disclosures.pdf" data-doi="10.1056/NEJMoa2027187">Download</a></li><li>426.51 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2027187_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2027187/suppl_file/nejmoa2027187_data-sharing.pdf" download="nejmoa2027187_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2027187_data-sharing.pdf" data-doi="10.1056/NEJMoa2027187">Download</a></li><li>90.14 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Soda M, Choi YL, Enomoto M, et al. Identification of the transforming <i>EML4-ALK</i> fusion gene in non-small-cell lung cancer. <em>Nature</em> 2007;448:561-566.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature05945" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17625570/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248446700036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer.&amp;publication_year=2007&amp;journal=Nature&amp;pages=561-566&amp;doi=10.1038%2Fnature05945&amp;pmid=17625570" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. <em>N Engl J Med</em> 2010;363:1693-1703.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2027187&amp;key=10.1056%2FNEJMoa1006448&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20979469/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000283546400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anaplastic+lymphoma+kinase+inhibition+in+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2010&amp;journal=N+Engl+J+Med&amp;pages=1693-1703&amp;doi=10.1056%2FNEJMoa1006448&amp;pmid=20979469" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in <i>ALK</i>-positive lung cancer. <em>N Engl J Med</em> 2014;371:2167-2177.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2027187&amp;key=10.1056%2FNEJMoa1408440&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25470694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345976700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+crizotinib+versus+chemotherapy+in+ALK-positive+lung+cancer.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=2167-2177&amp;doi=10.1056%2FNEJMoa1408440&amp;pmid=25470694" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to that of platinum–pemetrexed chemotherapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] -positive NSCLC </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated <i>ALK</i>-positive non–small-cell lung cancer. <em>N Engl J Med</em> 2017;377:829-838.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2027187&amp;key=10.1056%2FNEJMoa1704795&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28586279/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408626400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Alectinib+versus+crizotinib+in+untreated+ALK-positive+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=829-838&amp;doi=10.1056%2FNEJMoa1704795&amp;pmid=28586279" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] potent second-generation ALK inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] by an independent review committee. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of progression or death than crizotinib. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] primary analysis of the global ALEX trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] were 38%, 28%, and 27%, respectively. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in <i>ALK</i>-positive non–small-cell lung cancer. <em>N Engl J Med</em> 2018;379:2027-2039.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2027187&amp;key=10.1056%2FNEJMoa1810171&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30280657/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450816900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Brigatinib+versus+crizotinib+in+ALK-positive+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2027-2039&amp;doi=10.1056%2FNEJMoa1810171&amp;pmid=30280657" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] potent second-generation ALK inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] of progression or death than crizotinib. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Selvaggi G, Wakelee HA, Mok T, et al. Phase III randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (<i>ALK</i>) positive NSCLC patients: EXALT3. Presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer, Singapore, August 8, 2020. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Selvaggi+G%2C+Wakelee+HA%2C+Mok+T%2C+et+al.+Phase+III+randomized+study+of+ensartinib+vs+crizotinib+in+anaplastic+lymphoma+kinase+%28ALK%29+positive+NSCLC+patients%3A+EXALT3.+Presented+at+the+International+Association+for+the+Study+of+Lung+Cancer+World+Conference+on+Lung+Cancer%2C+Singapore%2C+August+8%2C+2020.+abstract." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for disease progression or death of 0.51. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] of progression or death than crizotinib. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] were 38%, 28%, and 27%, respectively. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the <i>EML4-ALK</i> fusion variant on the efficacy of alectinib in untreated <i>ALK</i>-positive advanced non-small cell lung cancer in the global Phase III ALEX Study. <em>J Thorac Oncol</em> 2019;14:1233-1243.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2019.03.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30902613/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000472506000022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Updated+efficacy+and+safety+data+and+impact+of+the+EML4-ALK+fusion+variant+on+the+efficacy+of+alectinib+in+untreated+ALK-positive+advanced+non-small+cell+lung+cancer+in+the+global+Phase+III+ALEX+Study.&amp;publication_year=2019&amp;journal=J+Thorac+Oncol&amp;pages=1233-1243&amp;doi=10.1016%2Fj.jtho.2019.03.007&amp;pmid=30902613" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] events than crizotinib (45% vs. 51%). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naive <i>ALK</i>-positive non-small cell lung cancer: second interim analysis of the Phase III ALTA-1L trial. <em>J Clin Oncol</em> 2020 August 11 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.20.00505" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32780660/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000588411100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Brigatinib+versus+crizotinib+in+advanced+ALK+inhibitor-naive+ALK-positive+non-small+cell+lung+cancer%3A+second+interim+analysis+of+the+Phase+III+ALTA-1L+trial.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;doi=10.1200%2FJCO.20.00505&amp;pmid=32780660" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for disease progression or death of 0.49. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] were 38%, 28%, and 27%, respectively. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] 3 or higher than crizotinib (73% vs. 61%), </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in <i>ALK</i>-rearranged lung cancer. <em>Cancer Discov</em> 2016;6:1118-1133.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/2159-8290.CD-16-0596" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27432227/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385642200022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Molecular+mechanisms+of+resistance+to+first-+and+second-generation+ALK+inhibitors+in+ALK-rearranged+lung+cancer.&amp;publication_year=2016&amp;journal=Cancer+Discov&amp;pages=1118-1133&amp;doi=10.1158%2F2159-8290.CD-16-0596&amp;pmid=27432227" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] drug resistance and recurrent disease </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] mutations that have been identified. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] first- or second-generation inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] receiving second-generation inhibitors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Katayama R, Friboulet L, Koike S, et al. Two novel <i>ALK</i> mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. <em>Clin Cancer Res</em> 2014;20:5686-5696.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-14-1511" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25228534/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345130800014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Two+novel+ALK+mutations+mediate+acquired+resistance+to+the+next-generation+ALK+inhibitor+alectinib.&amp;publication_year=2014&amp;journal=Clin+Cancer+Res&amp;pages=5686-5696&amp;doi=10.1158%2F1078-0432.CCR-14-1511&amp;pmid=25228534" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Dagogo-Jack I, Oxnard GR, Fink J, et al. A phase II study of lorlatinib in patients (pts) with <i>ALK</i>-positive (ALK+) lung cancer with brain-only progression. <em>J Clin Oncol</em> 2020;38:Suppl 15:9595-9595. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2020.38.15_suppl.9595" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+II+study+of+lorlatinib+in+patients+%28pts%29+with+ALK-positive+%28ALK%2B%29+lung+cancer+with+brain-only+progression&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=9595-9595&amp;doi=10.1200%2FJCO.2020.38.15_suppl.9595" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cause of illness and death — still develop. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] disease, including leptomeningeal disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Bauer TM, Shaw AT, Johnson ML, et al. Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated <i>ALK</i>-positive non-small-cell lung cancer. <em>Target Oncol</em> 2020;15:55-65.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11523-020-00702-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32060867/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000514800300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Brain+penetration+of+lorlatinib%3A+cumulative+incidences+of+CNS+and+non-CNS+progression+with+lorlatinib+in+patients+with+previously+treated+ALK-positive+non-small-cell+lung+cancer.&amp;publication_year=2020&amp;journal=Target+Oncol&amp;pages=55-65&amp;doi=10.1007%2Fs11523-020-00702-4&amp;pmid=32060867" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cause of illness and death — still develop. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] disease, including leptomeningeal disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Gainor JF, Chi AS, Logan J, et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. <em>J Thorac Oncol</em> 2016;11:256-260.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2015.10.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26845119/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373094300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Alectinib+dose+escalation+reinduces+central+nervous+system+responses+in+patients+with+anaplastic+lymphoma+kinase-positive+non-small+cell+lung+cancer+relapsing+on+standard+dose+alectinib.&amp;publication_year=2016&amp;journal=J+Thorac+Oncol&amp;pages=256-260&amp;doi=10.1016%2Fj.jtho.2015.10.010&amp;pmid=26845119" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. <em>Curr Oncol</em> 2013;20(4):e300-e306.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3747/co.20.1481" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23904768/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000322782400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Survival+of+patients+with+non-small-cell+lung+cancer+after+a+diagnosis+of+brain+metastases.&amp;publication_year=2013&amp;journal=Curr+Oncol&amp;pages=e300-e306&amp;doi=10.3747%2Fco.20.1481&amp;pmid=23904768" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Venur VA, Ahluwalia MS. Targeted therapy in brain metastases: ready for primetime? <em>Am Soc Clin Oncol Educ Book</em> 2016;35:e123-e130.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/EDBK_100006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27249714/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeted+therapy+in+brain+metastases%3A+ready+for+primetime%3F&amp;publication_year=2016&amp;journal=Am+Soc+Clin+Oncol+Educ+Book&amp;pages=e123-e130&amp;doi=10.1200%2FEDBK_100006&amp;pmid=27249714" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. <em>Cancer Cell</em> 2015;28:70-81.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ccell.2015.05.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26144315/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358111300011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PF-06463922%2C+an+ALK%2FROS1+inhibitor%2C+overcomes+resistance+to+first+and+second+generation+ALK+inhibitors+in+preclinical+models.&amp;publication_year=2015&amp;journal=Cancer+Cell&amp;pages=70-81&amp;doi=10.1016%2Fj.ccell.2015.05.010&amp;pmid=26144315" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations that have been identified. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] first- or second-generation inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] effective in treating CNS metastases. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Horn L, Whisenant JG, Wakelee H, et al. Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. <em>J Thorac Oncol</em> 2019;14:1901-1911.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2019.08.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31446141/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000492678300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Monitoring+therapeutic+response+and+resistance%3A+analysis+of+circulating+tumor+DNA+in+patients+with+ALK%2B+lung+cancer.&amp;publication_year=2019&amp;journal=J+Thorac+Oncol&amp;pages=1901-1911&amp;doi=10.1016%2Fj.jtho.2019.08.003&amp;pmid=31446141" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations that have been identified. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] first- or second-generation inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] receiving second-generation inhibitors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10<i>R</i>)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2<i>H</i>-8,4-(metheno)pyrazolo[4,3-<i>h</i>][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. <em>J Med Chem</em> 2014;57:4720-4744.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1021/jm500261q" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24819116/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000337336600023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations.&amp;publication_year=2014&amp;journal=J+Med+Chem&amp;pages=4720-4744&amp;doi=10.1021%2Fjm500261q&amp;pmid=24819116" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] order to achieve high exposures in the CNS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] tropomyosin receptor kinase B in the CNS. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with <i>ALK</i> or <i>ROS1</i> rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <em>Lancet Oncol</em> 2017;18:1590-1599.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30680-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29074098/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417001900038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lorlatinib+in+non-small-cell+lung+cancer+with+ALK+or+ROS1+rearrangement%3A+an+international%2C+multicentre%2C+open-label%2C+single-arm+first-in-man+phase+1+trial.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=1590-1599&amp;doi=10.1016%2FS1470-2045%2817%2930680-0&amp;pmid=29074098" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] order to achieve high exposures in the CNS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] second-generation, or both). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 1 and reversible with dose interruption. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] effective in treating CNS metastases. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] to that reported in previous studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] with dose interruption and reduction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with <i>ALK</i>-positive non-small-cell lung cancer: results from a global phase 2 study. <em>Lancet Oncol</em> 2018;19:1654-1667.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(18)30649-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30413378/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451633800060" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lorlatinib+in+patients+with+ALK-positive+non-small-cell+lung+cancer%3A+results+from+a+global+phase+2+study.&amp;publication_year=2018&amp;journal=Lancet+Oncol&amp;pages=1654-1667&amp;doi=10.1016%2FS1470-2045%2818%2930649-1&amp;pmid=30413378" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] second-generation, or both). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] disease, including leptomeningeal disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 1 and reversible with dose interruption. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] resistance mutations. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] ranging from 14.5 months to not reached. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] response was even higher, at 87%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] to that reported in previous studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] with dose interruption and reduction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys <i>BRAF</i>-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <em>Lancet Oncol</em> 2012;13:1087-1095.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(12)70431-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23051966/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000310570900039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dabrafenib+in+patients+with+Val600Glu+or+Val600Lys+BRAF-mutant+melanoma+metastatic+to+the+brain+%28BREAK-MB%29%3A+a+multicentre%2C+open-label%2C+phase+2+trial.&amp;publication_year=2012&amp;journal=Lancet+Oncol&amp;pages=1087-1095&amp;doi=10.1016%2FS1470-2045%2812%2970431-X&amp;pmid=23051966" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib. <em>Oncologist</em> 2019;24:1103-1110.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.2018-0380" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30890623/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000481426100036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+management+of+adverse+events+associated+with+lorlatinib.&amp;publication_year=2019&amp;journal=Oncologist&amp;pages=1103-1110&amp;doi=10.1634%2Ftheoncologist.2018-0380&amp;pmid=30890623" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 1 and reversible with dose interruption. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with dose interruption and reduction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] may be associated with increased appetite. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] Supplementary Appendix). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Reed M, Rosales A-LS, Chioda MD, Parker L, Devgan G, Kettle J. Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. <em>Adv Ther</em> 2020;37:3019-3030.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12325-020-01365-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32399810/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000532097000004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Consensus+recommendations+for+management+and+counseling+of+adverse+events+associated+with+lorlatinib%3A+a+guide+for+healthcare+practitioners.&amp;publication_year=2020&amp;journal=Adv+Ther&amp;pages=3019-3030&amp;doi=10.1007%2Fs12325-020-01365-3&amp;pmid=32399810" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 1 and reversible with dose interruption. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with dose interruption and reduction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Supplementary Appendix). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Soria J-C, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced <i>ALK</i>-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <em>Lancet</em> 2017;389:917-929.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)30123-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28126333/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000395263400031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+ceritinib+versus+platinum-based+chemotherapy+in+advanced+ALK-rearranged+non-small-cell+lung+cancer+%28ASCEND-4%29%3A+a+randomised%2C+open-label%2C+phase+3+study.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=917-929&amp;doi=10.1016%2FS0140-6736%2817%2930123-X&amp;pmid=28126333" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Shaw AT, Solomon BJ, Besse B, et al. <i>ALK</i> resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. <em>J Clin Oncol</em> 2019;37:1370-1379.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.18.02236" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30892989/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471946600003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ALK+resistance+mutations+and+efficacy+of+lorlatinib+in+advanced+anaplastic+lymphoma+kinase-positive+non-small-cell+lung+cancer.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=1370-1379&amp;doi=10.1200%2FJCO.18.02236&amp;pmid=30892989" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. <em>J Clin Oncol</em> 2011;29(15):e443-e445.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2010.34.1313" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21422405/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000290716900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CSF+concentration+of+the+anaplastic+lymphoma+kinase+inhibitor+crizotinib.&amp;publication_year=2011&amp;journal=J+Clin+Oncol&amp;pages=e443-e445&amp;doi=10.1200%2FJCO.2010.34.1313&amp;pmid=21422405" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced <i>ROS1</i>-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. <em>Lancet Oncol</em> 2019;20:1691-1701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(19)30655-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31669155/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500750400049" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lorlatinib+in+advanced+ROS1-positive+non-small-cell+lung+cancer%3A+a+multicentre%2C+open-label%2C+single-arm%2C+phase+1-2+trial.&amp;publication_year=2019&amp;journal=Lancet+Oncol&amp;pages=1691-1701&amp;doi=10.1016%2FS1470-2045%2819%2930655-2&amp;pmid=31669155" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Drilon A. TRK inhibitors in TRK fusion-positive cancers. <em>Ann Oncol</em> 2019;30:Suppl 8:viii23-viii30.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz282" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31738426/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000501727600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TRK+inhibitors+in+TRK+fusion-positive+cancers.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=viii23-viii30&amp;doi=10.1093%2Fannonc%2Fmdz282&amp;pmid=31738426" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/21"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">21</span></span> • <span property="datePublished">November 19, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2018</span>-<span property="pageEnd">2029</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2027187" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2027187?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: November 18, 2020</div><div><b class="core-label">Published in issue</b>: November 19, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/lung-cancer" alt="View article keyword Lung Cancer" data-interactiontype="article_recirculation_click">Lung Cancer</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Alice T.</span> <span property="familyName">Shaw</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Todd M.</span> <span property="familyName">Bauer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Filippo</span> <span property="familyName">de Marinis</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Enriqueta</span> <span property="familyName">Felip</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yasushi</span> <span property="familyName">Goto</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Geoffrey</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Julien</span> <span property="familyName">Mazieres</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dong-Wan</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tony</span> <span property="familyName">Mok</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anna</span> <span property="familyName">Polli</span>, <span property="honorificSuffix">B.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Holger</span> <span property="familyName">Thurm</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anna M.</span> <span property="familyName">Calella</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gerson</span> <span property="familyName">Peltz</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Benjamin J.</span> <span property="familyName">Solomon</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span>, for <span property="author" typeof="Person">the CROWN Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) — both in Boston; Sarah Cannon Research Institute–Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) — both in Milan; Vall d’Hebron University Hospital and Institute of Oncology, International Oncology Bureau–Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Shaw at the Massachusetts General Hospital Cancer Center, 32 Fruit St., Boston, MA 02114, or at: <a href="mailto:ashaw1@mgh.harvard.edu">ashaw1@mgh.harvard.edu</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the CROWN trial investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">756</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2027187" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="6df7ee2e-590a-1569-c1c6-0e668cad6914"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94560071" style="display:inline-block;">
                <img alt="Article has an altmetric score of 296" src="https://badges.altmetric.com/?size=320&amp;score=296&amp;types=mabcttfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94560071">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_6df7ee2e-590a-1569-c1c6-0e668cad6914" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94560071&amp;tab=news">
          Picked up by <b>25</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94560071&amp;tab=blogs">
          Blogged by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94560071&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94560071&amp;tab=twitter">
          Posted by <b>143</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94560071&amp;tab=patents">
          Referenced in <b>6</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94560071&amp;tab=facebook">
          On <b>3</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94560071&amp;tab=guidelines">
          Referenced in <b>4</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>577</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d656d4e3c0af23-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2027187"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-21%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2027187%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="756" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Fei Gao, </li><li class="list-inline-item cited-by__entry__author">Zhenhua Wu, </li><li class="list-inline-item cited-by__entry__author">Anqi Lin, </li><li class="list-inline-item cited-by__entry__author">Xinyu Wu, </li><li class="list-inline-item cited-by__entry__author">Baoding Zhang, </li><li class="list-inline-item cited-by__entry__author">Liqing Liu, </li><li class="list-inline-item cited-by__entry__author">Yue Lu, </li><li class="list-inline-item cited-by__entry__author">Shangshang Geng, </li><li class="list-inline-item cited-by__entry__author">Zhen Huang, </li><li class="list-inline-item cited-by__entry__author">Yiyu Chen, </li><li class="list-inline-item cited-by__entry__author">Jianming Zhang, </li><li class="list-inline-item cited-by__entry__author">Li Li, </li><li class="list-inline-item cited-by__entry__author">Xianming Deng, </li></ul><span class="cited-by__entry__title">Discovery of an ALK degrader for lorlatinib-resistant compound mutations, </span><span class="cited-by__entry__series-title">European Journal of Medicinal Chemistry, </span><span class="cited-by__entry__volume"><strong>296</strong>, </span><span class="cited-by__entry__page-range">(117835), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ejmech.2025.117835" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ejmech.2025.117835</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ejmech.2025.117835" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Federica Miglietta, </li><li class="list-inline-item cited-by__entry__author">Mario Pirozzi, </li><li class="list-inline-item cited-by__entry__author">Michele Bottosso, </li><li class="list-inline-item cited-by__entry__author">Carla Pisani, </li><li class="list-inline-item cited-by__entry__author">Pierfrancesco Franco, </li><li class="list-inline-item cited-by__entry__author">Valentina Guarnieri, </li><li class="list-inline-item cited-by__entry__author">Alessandra Gennari, </li></ul><span class="cited-by__entry__title">Anaemia in cancer patients: Advances and challenges in the era of precision oncology, </span><span class="cited-by__entry__series-title">Critical Reviews in Oncology/Hematology, </span><span class="cited-by__entry__volume"><strong>213</strong>, </span><span class="cited-by__entry__page-range">(104788), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.critrevonc.2025.104788" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.critrevonc.2025.104788</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.critrevonc.2025.104788" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Qiu-Ge Liu, </li><li class="list-inline-item cited-by__entry__author">Ji Wu, </li><li class="list-inline-item cited-by__entry__author">Zi-Yue Wang, </li><li class="list-inline-item cited-by__entry__author">Bing-Bing Chen, </li><li class="list-inline-item cited-by__entry__author">Yi-Fei Du, </li><li class="list-inline-item cited-by__entry__author">Jin-Bo Niu, </li><li class="list-inline-item cited-by__entry__author">Jian Song, </li><li class="list-inline-item cited-by__entry__author">Sai-Yang Zhang, </li></ul><span class="cited-by__entry__title">ALK-based dual inhibitors: Focus on recent development for non-small cell lung cancer therapy, </span><span class="cited-by__entry__series-title">European Journal of Medicinal Chemistry, </span><span class="cited-by__entry__volume"><strong>291</strong>, </span><span class="cited-by__entry__page-range">(117646), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ejmech.2025.117646" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ejmech.2025.117646</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ejmech.2025.117646" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Gen Lin, </li><li class="list-inline-item cited-by__entry__author">Yongsheng Wang, </li><li class="list-inline-item cited-by__entry__author">Tao Xin, </li><li class="list-inline-item cited-by__entry__author">Ding Zhang, </li><li class="list-inline-item cited-by__entry__author">Qiuyu Zhang, </li><li class="list-inline-item cited-by__entry__author">Yangsi Li, </li><li class="list-inline-item cited-by__entry__author">Yudan Chi, </li><li class="list-inline-item cited-by__entry__author">Yun Fan, </li><li class="list-inline-item cited-by__entry__author">Anwen Liu, </li><li class="list-inline-item cited-by__entry__author">Haipeng Xu, </li><li class="list-inline-item cited-by__entry__author">Liang Shi, </li><li class="list-inline-item cited-by__entry__author">Longfeng Zhang, </li><li class="list-inline-item cited-by__entry__author">Qian Miao, </li><li class="list-inline-item cited-by__entry__author">Xiaobin Zheng, </li><li class="list-inline-item cited-by__entry__author">Lijun Li, </li><li class="list-inline-item cited-by__entry__author">Kaijia Zhou, </li><li class="list-inline-item cited-by__entry__author">Qiwei Yao, </li><li class="list-inline-item cited-by__entry__author">Zihua Zou, </li><li class="list-inline-item cited-by__entry__author">Kang Miao, </li><li class="list-inline-item cited-by__entry__author">Yaping Hong, </li></ul><span class="cited-by__entry__title">Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer, </span><span class="cited-by__entry__series-title">Thoracic Cancer, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__issue">11, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/1759-7714.70088" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/1759-7714.70088</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/1759-7714.70088" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">J.W.T. van der Wel, </li><li class="list-inline-item cited-by__entry__author">A.J. de Langen, </li></ul><span class="cited-by__entry__title">Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting, </span><span class="cited-by__entry__series-title">Lung Cancer, </span><span class="cited-by__entry__volume"><strong>204</strong>, </span><span class="cited-by__entry__page-range">(108490), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.lungcan.2025.108490" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.lungcan.2025.108490</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.lungcan.2025.108490" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jiahong Jiang, </li><li class="list-inline-item cited-by__entry__author">Luying Zhan, </li><li class="list-inline-item cited-by__entry__author">Boyang Jiang, </li><li class="list-inline-item cited-by__entry__author">Jingyi Pan, </li><li class="list-inline-item cited-by__entry__author">Chaojin Hong, </li><li class="list-inline-item cited-by__entry__author">Zheling Chen, </li><li class="list-inline-item cited-by__entry__author">Liu Yang, </li></ul><span class="cited-by__entry__title">Anticancer therapy-induced peripheral neuropathy in solid tumors: diagnosis, mechanisms, and treatment strategies, </span><span class="cited-by__entry__series-title">Cancer Letters, </span><span class="cited-by__entry__volume"><strong>620</strong>, </span><span class="cited-by__entry__page-range">(217679), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.canlet.2025.217679" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.canlet.2025.217679</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.canlet.2025.217679" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Oliver Gautschi, </li><li class="list-inline-item cited-by__entry__author">Keunchil Park, </li><li class="list-inline-item cited-by__entry__author">Benjamin J. Solomon, </li><li class="list-inline-item cited-by__entry__author">Pascale Tomasini, </li><li class="list-inline-item cited-by__entry__author">Herbert H. Loong, </li><li class="list-inline-item cited-by__entry__author">Filippo De Braud, </li><li class="list-inline-item cited-by__entry__author">Koichi Goto, </li><li class="list-inline-item cited-by__entry__author">Patrick Peterson, </li><li class="list-inline-item cited-by__entry__author">Scott Barker, </li><li class="list-inline-item cited-by__entry__author">Katherine Liming, </li><li class="list-inline-item cited-by__entry__author">Geoffrey R. Oxnard, </li><li class="list-inline-item cited-by__entry__author">Bente Frimodt-Moller, </li><li class="list-inline-item cited-by__entry__author">Alexander Drilon, </li></ul><span class="cited-by__entry__title">
              Selpercatinib in
              RET
              Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
            , </span><span class="cited-by__entry__series-title">Journal of Clinical Oncology, </span><span class="cited-by__entry__volume"><strong>43</strong>, </span><span class="cited-by__entry__issue">15, </span><span class="cited-by__entry__page-range">(1758-1764), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1200/JCO-24-02076" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1200/JCO-24-02076</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1200/JCO-24-02076" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Shoki Izumi, </li><li class="list-inline-item cited-by__entry__author">Shogo Nomura, </li><li class="list-inline-item cited-by__entry__author">Yutaka Matsuyama, </li></ul><span class="cited-by__entry__title">Adjustment of Conditional Bias in Hazard Ratios for Group Sequential Testing of Progression‐Free Survival and Overall Survival, </span><span class="cited-by__entry__series-title">Statistics in Medicine, </span><span class="cited-by__entry__volume"><strong>44</strong>, </span><span class="cited-by__entry__issue">10-12, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/sim.70112" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/sim.70112</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/sim.70112" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nejat Emre Öksüz, </li><li class="list-inline-item cited-by__entry__author">Ergin Aydemir, </li><li class="list-inline-item cited-by__entry__author">Kadriye Bir Yucel, </li></ul><span class="cited-by__entry__title">Reevaluating the prognostic impact of spread through air spaces and lymphovascular invasion in resected non-small cell lung cancer: the role of systemic therapy in survival outcomes, </span><span class="cited-by__entry__series-title">Updates in Surgery, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s13304-025-02259-1" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s13304-025-02259-1</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s13304-025-02259-1" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Oscar Arrieta, </li><li class="list-inline-item cited-by__entry__author">Luis Lara-Mejía, </li><li class="list-inline-item cited-by__entry__author">Eduardo Rios-Garcia, </li><li class="list-inline-item cited-by__entry__author">Enrique Caballé-Perez, </li><li class="list-inline-item cited-by__entry__author">Luis Cabrera-Miranda, </li><li class="list-inline-item cited-by__entry__author">Maritza Ramos-Ramírez, </li><li class="list-inline-item cited-by__entry__author">David Dávila-Dupont, </li><li class="list-inline-item cited-by__entry__author">Andrés F. Cardona, </li><li class="list-inline-item cited-by__entry__author">Graciela Cruz-Rico, </li><li class="list-inline-item cited-by__entry__author">Jordi Remon, </li><li class="list-inline-item cited-by__entry__author">Alexandra Garcilazo-Reyes, </li><li class="list-inline-item cited-by__entry__author">Rafael Rosell, </li></ul><span class="cited-by__entry__title">Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial, </span><span class="cited-by__entry__series-title">Nature Communications, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41467-025-59744-9" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41467-025-59744-9</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41467-025-59744-9" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-21%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2027187%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2027187" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2027187" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2027187.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f1.jpg"><img src="/cms/10.1056/NEJMoa2027187/asset/36201cc3-90d7-4f2c-af4e-53d9075534ee/assets/images/large/nejmoa2027187_f1.jpg" height="3097" width="2231" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Randomization, Treatment, and Follow-up.</div><div class="notes"><div role="doc-footnote">A total of 296 patients were randomly assigned to receive either lorlatinib or crizotinib. The intention-to-treat population included all the patients who underwent randomization. The as-treated population included all the patients who received at least one dose of lorlatinib or crizotinib.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f2.jpg"><img src="/cms/10.1056/NEJMoa2027187/asset/19964ad5-4b64-455b-8a1f-7888ee796a58/assets/images/large/nejmoa2027187_f2.jpg" height="3374" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Efficacy Outcomes in the Intention-to-Treat Population.</div><div class="notes"><div role="doc-footnote">Panel A shows Kaplan–Meier estimates of progression-free survival, according to blinded independent central review (BICR) in the intention-to-treat population. Progression-free survival was significantly longer with lorlatinib than crizotinib; the median progression-free survival with lorlatinib was not reached. Tick marks on the survival curves indicate censoring of data. NR denotes not reached. Panel B shows Kaplan–Meier estimates of time to intracranial progression, as assessed by BICR, in the intention-to-treat population. Time to intracranial progression was defined as the time from randomization to the first objective progression of central nervous system (CNS) disease (either new brain metastases or progression of existing brain metastases). Panel C shows the cumulative incidence of CNS progression as the first event, as assessed by BICR in the intention-to-treat population. Cumulative-incidence probabilities were calculated with the use of a competing-risks approach, with values adjusted for the competing risks of non-CNS progression and death (Fig. S3 in the <a href="#ap2">Supplementary Appendix</a>). Panel D shows Kaplan–Meier curves of overall survival.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2027187/asset/1b228182-ad15-4280-8b26-572caf533e13/assets/images/large/nejmoa2027187_t1.jpg" height="2721" width="1136" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Lorlatinib<br>(N=149)</th><th class="txxr-borders">Crizotinib<br>(N=147)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age — yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">59.1±13.1</td><td class="xxxr-borders">55.6±13.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">61</td><td class="xxxr-borders shading">56</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Interquartile range</td><td class="xxxx-borders">51–69</td><td class="xxxr-borders">45–66</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Sex — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">84 (56)</td><td class="xxxr-borders">91 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">65 (44)</td><td class="xxxr-borders shading">56 (38)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Race or ethnic group — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">72 (48)</td><td class="xxxr-borders shading">72 (49)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">65 (44)</td><td class="xxxr-borders">65 (44)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Missing</td><td class="xxxx-borders">12 (8)</td><td class="xxxr-borders">9 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance-status score — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">67 (45)</td><td class="xxxr-borders">57 (39)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">79 (53)</td><td class="xxxr-borders shading">81 (55)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">9 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Smoking status — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Never smoked</td><td class="xxxx-borders">81 (54)</td><td class="xxxr-borders">94 (64)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Previous smoker</td><td class="xxxx-borders shading">55 (37)</td><td class="xxxr-borders shading">43 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Current smoker</td><td class="xxxx-borders">13 (9)</td><td class="xxxr-borders">9 (6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Current stage of disease — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">IIIA</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">IIIB</td><td class="xxxx-borders shading">12 (8)</td><td class="xxxr-borders shading">8 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">IV</td><td class="xxxx-borders">135 (91)</td><td class="xxxr-borders">139 (95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Histologic type — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adenocarcinoma</td><td class="xxxx-borders shading">140 (94)</td><td class="xxxr-borders shading">140 (95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adenosquamous carcinoma</td><td class="xxxx-borders">6 (4)</td><td class="xxxr-borders">5 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Large-cell carcinoma</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Squamous-cell carcinoma</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Use of previous anticancer drug therapy — no. (%)<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">12 (8)</td><td class="xxxr-borders shading">9 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Previous brain radiotherapy — no. (%)</td><td class="xxxx-borders">9 (6)</td><td class="xxxr-borders">10 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Brain metastases at baseline — no. (%)</td><td class="xbxx-borders shading">38 (26)</td><td class="xbxr-borders shading">40 (27)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race or ethnic group was reported by the investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5, with higher scores indicating greater disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Smoking status was not reported for one patient in the crizotinib group.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">The disease stage in one patient who had locally advanced disease at trial entry was defined according to the American Joint Committee on Cancer (AJCC), version 8.0, instead of AJCC, version 7.0, as required by the protocol. This stage was therefore classified as “other.”</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">According to the protocol, previous adjuvant or neoadjuvant anticancer therapy was allowed if it had been completed more than 12 months before randomization. One patient who had received previous chemotherapy for metastatic disease was reported as having a protocol violation.</div></div></div></figcaption></a><figcaption><div class="caption">Baseline Patient Characteristics in the Intention-to-Treat Population.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2027187/asset/7890bf10-33f5-4f07-8514-c225a385f3fc/assets/images/large/nejmoa2027187_t2.jpg" height="2195" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Lorlatinib</th><th class="txxx-borders">Crizotinib</th><th class="txxr-borders">Odds Ratio<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Intention-to-treat population</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">149</td><td class="xxxx-borders">147</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Confirmed objective response</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients</td><td class="xxxx-borders">113</td><td class="xxxx-borders">85</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">% (95% CI)</td><td class="xxxx-borders shading">76 (68–83)</td><td class="xxxx-borders shading">58 (49–66)</td><td class="xxxr-borders shading">2.25 (1.35–3.89)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response — no. (%)</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response — no. (%)</td><td class="xxxx-borders shading">109 (73)</td><td class="xxxx-borders shading">85 (58)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Stable disease — no. (%)</td><td class="xxxx-borders">19 (13)</td><td class="xxxx-borders">41 (28)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Neither complete response nor progressive disease — no. (%)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Progressive disease — no. (%)</td><td class="xxxx-borders">10 (7)</td><td class="xxxx-borders">7 (5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Could not be evaluated — no. (%)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">NE (NE–NE)</td><td class="xxxx-borders">11.0 (9.0–12.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time to tumor response (IQR) — mo</td><td class="xxxx-borders shading">1.8 (1.7–1.9)</td><td class="xxxx-borders shading">1.8 (1.7–1.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Patients with measurable or nonmeasurable brain metastases at</b> <b>baseline</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">38</td><td class="xxxx-borders shading">40</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Confirmed CNS response</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">25</td><td class="xxxx-borders shading">8</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">% (95% CI)</td><td class="xxxx-borders">66 (49–80)</td><td class="xxxx-borders">20 (9–36)</td><td class="xxxr-borders">8.41 (2.59–27.23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CNS complete response — no. (%)</td><td class="xxxx-borders shading">23 (61)</td><td class="xxxx-borders shading">6 (15)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">NE (NE–NE)</td><td class="xxxx-borders">9.4 (6.0–11.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median time to tumor response (IQR) — mo</td><td class="xxxx-borders shading">1.9 (1.8–3.7)</td><td class="xxxx-borders shading">1.8 (1.7–2.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Patients with measurable brain metastases at</b> <b>baseline</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">13</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Confirmed CNS response</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">% (95% CI)</td><td class="xxxx-borders">82 (57–96)</td><td class="xxxx-borders">23 (5–54)</td><td class="xxxr-borders">16.83 (1.95–163.23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CNS complete response — no. (%)</td><td class="xxxx-borders shading">12 (71)</td><td class="xxxx-borders shading">1 (8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">NE (NE–NE)</td><td class="xxxx-borders">10.2 (9.4–11.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Median time to tumor response (IQR) — mo</td><td class="xbxx-borders shading">1.9 (1.8–3.5)</td><td class="xbxx-borders shading">1.9 (1.8–1.9)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Responses in patients with brain metastases at baseline were assessed by blinded independent central review. An odds ratio greater than 1 indicates a better outcome with lorlatinib than with crizotinib. CI denotes confidence interval, CNS central nervous system, IQR interquartile range, and NE could not be evaluated.</div></div></div></figcaption></a><figcaption><div class="caption">Objective Response in the Intention-to-Treat Population and among Patients with Brain Metastases at Baseline.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2027187/asset/a7327bf9-ad16-42ce-94ca-c56b099c8fb0/assets/images/large/nejmoa2027187_t3.jpg" height="2013" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><td class="txlx-borders">&nbsp;</td><th class="txxx-borders" colspan="5"><span>Lorlatinib (N=149)</span></th><th class="txxr-borders" colspan="5"><span>Crizotinib (N=142)</span></th></tr><tr class="head2" data-type="row head2"><th class="xxlx-borders" data-xml-align="left">Event</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 1</th><th class="xxxx-borders">Grade 2</th><th class="xxxx-borders">Grade 3</th><th class="xxxx-borders">Grade 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 1</th><th class="xxxx-borders">Grade 2</th><th class="xxxx-borders">Grade 3</th><th class="xxxr-borders">Grade 4</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="10"><span><i>number of patients (percent)</i></span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">149 (100)</td><td class="xxxx-borders shading">6 (4)</td><td class="xxxx-borders shading">28 (19)</td><td class="xxxx-borders shading">87 (58)</td><td class="xxxx-borders shading">21 (14)</td><td class="xxxx-borders shading">140 (99)</td><td class="xxxx-borders shading">8 (6)</td><td class="xxxx-borders shading">46 (32)</td><td class="xxxx-borders shading">67 (47)</td><td class="xxxr-borders shading">12 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hypercholesterolemia<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">105 (70)</td><td class="xxxx-borders">24 (16)</td><td class="xxxx-borders">57 (38)</td><td class="xxxx-borders">23 (15)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">5 (4)</td><td class="xxxx-borders">5 (4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertriglyceridemia<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">95 (64)</td><td class="xxxx-borders shading">28 (19)</td><td class="xxxx-borders shading">37 (25)</td><td class="xxxx-borders shading">19 (13)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxx-borders shading">8 (6)</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Edema<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">82 (55)</td><td class="xxxx-borders">54 (36)</td><td class="xxxx-borders">22 (15)</td><td class="xxxx-borders">6 (4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">56 (39)</td><td class="xxxx-borders">38 (27)</td><td class="xxxx-borders">16 (11)</td><td class="xxxx-borders">2 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Increased weight</td><td class="xxxx-borders shading">57 (38)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxx-borders shading">21 (14)</td><td class="xxxx-borders shading">25 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">18 (13)</td><td class="xxxx-borders shading">6 (4)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Peripheral neuropathy<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">50 (34)</td><td class="xxxx-borders">36 (24)</td><td class="xxxx-borders">11 (7)</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">21 (15)</td><td class="xxxx-borders">19 (13)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Cognitive effects<a href="#core-t3fn2" role="doc-noteref">†</a><a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">32 (21)</td><td class="xxxx-borders shading">20 (13)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (6)</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">32 (21)</td><td class="xxxx-borders">21 (14)</td><td class="xxxx-borders">9 (6)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">74 (52)</td><td class="xxxx-borders">67 (47)</td><td class="xxxx-borders">6 (4)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">29 (19)</td><td class="xxxx-borders shading">16 (11)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">11 (8)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">29 (19)</td><td class="xxxx-borders">25 (17)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">46 (32)</td><td class="xxxx-borders">25 (18)</td><td class="xxxx-borders">17 (12)</td><td class="xxxx-borders">4 (3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">27 (18)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxx-borders shading">15 (10)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Vision disorder<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">27 (18)</td><td class="xxxx-borders">25 (17)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">56 (39)</td><td class="xxxx-borders">54 (38)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Increased ALT level</td><td class="xxxx-borders shading">26 (17)</td><td class="xxxx-borders shading">22 (15)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">48 (34)</td><td class="xxxx-borders shading">26 (18)</td><td class="xxxx-borders shading">16 (11)</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Constipation</td><td class="xxxx-borders">26 (17)</td><td class="xxxx-borders">24 (16)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">42 (30)</td><td class="xxxx-borders">30 (21)</td><td class="xxxx-borders">11 (8)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Mood effects<a href="#core-t3fn2" role="doc-noteref">†</a><a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">24 (16)</td><td class="xxxx-borders shading">14 (9)</td><td class="xxxx-borders shading">8 (5)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">22 (15)</td><td class="xxxx-borders">21 (14)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">74 (52)</td><td class="xxxx-borders">56 (39)</td><td class="xxxx-borders">15 (11)</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Increased AST level</td><td class="xxxx-borders shading">21 (14)</td><td class="xxxx-borders shading">18 (12)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">39 (27)</td><td class="xxxx-borders shading">30 (21)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Vomiting</td><td class="xxxx-borders">19 (13)</td><td class="xxxx-borders">16 (11)</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">55 (39)</td><td class="xxxx-borders">42 (30)</td><td class="xxxx-borders">11 (8)</td><td class="xxxx-borders">2 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hyperlipidemia</td><td class="xxxx-borders shading">16 (11)</td><td class="xxxx-borders shading">6 (4)</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Dysgeusia</td><td class="xxxx-borders">8 (5)</td><td class="xxxx-borders">8 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">23 (16)</td><td class="xxxx-borders">20 (14)</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">35 (25)</td><td class="xxxx-borders shading">23 (16)</td><td class="xxxx-borders shading">8 (6)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Bradycardia</td><td class="xbxx-borders">2 (1)</td><td class="xbxx-borders">2 (1)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">17 (12)</td><td class="xbxx-borders">15 (11)</td><td class="xbxx-borders">2 (1)</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Shown are adverse events that differed by more than 10 percentage points in frequency between the groups. Patients were counted only once per event. The listed events occurred after the first dose of trial treatment through the end of trial follow-up or the start of new anticancer therapy, whichever took place first. Data for all grades in the lorlatinib group are listed in decreasing order of frequency. ALT denotes alanine aminotransferase, and AST aspartate aminotransferase.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">This category comprised a cluster of adverse events that may represent similar clinical symptoms or syndromes.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Cognitive effects with a frequency of at least 1% included memory impairment, disturbance in attention, confusion, amnesia, cognitive disorder, and delirium.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">Mood effects with a frequency of at least 1% included anxiety, depression, affect lability, affective disorder, agitation, irritability, and altered mood.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events in the Safety Population.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2027187_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2027187</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Soda M, Choi YL, Enomoto M, et al. Identification of the transforming <i>EML4-ALK</i> fusion gene in non-small-cell lung cancer. <em>Nature</em> 2007;448:561-566.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature05945" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17625570/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248446700036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer.&amp;publication_year=2007&amp;journal=Nature&amp;pages=561-566&amp;doi=10.1038%2Fnature05945&amp;pmid=17625570" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. <em>N Engl J Med</em> 2010;363:1693-1703.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2027187&amp;key=10.1056%2FNEJMoa1006448&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20979469/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000283546400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anaplastic+lymphoma+kinase+inhibition+in+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2010&amp;journal=N+Engl+J+Med&amp;pages=1693-1703&amp;doi=10.1056%2FNEJMoa1006448&amp;pmid=20979469" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in <i>ALK</i>-positive lung cancer. <em>N Engl J Med</em> 2014;371:2167-2177.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2027187&amp;key=10.1056%2FNEJMoa1408440&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25470694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345976700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+crizotinib+versus+chemotherapy+in+ALK-positive+lung+cancer.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=2167-2177&amp;doi=10.1056%2FNEJMoa1408440&amp;pmid=25470694" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to that of platinum–pemetrexed chemotherapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] -positive NSCLC </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated <i>ALK</i>-positive non–small-cell lung cancer. <em>N Engl J Med</em> 2017;377:829-838.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2027187&amp;key=10.1056%2FNEJMoa1704795&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28586279/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408626400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Alectinib+versus+crizotinib+in+untreated+ALK-positive+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=829-838&amp;doi=10.1056%2FNEJMoa1704795&amp;pmid=28586279" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] potent second-generation ALK inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] by an independent review committee. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of progression or death than crizotinib. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] primary analysis of the global ALEX trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] were 38%, 28%, and 27%, respectively. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in <i>ALK</i>-positive non–small-cell lung cancer. <em>N Engl J Med</em> 2018;379:2027-2039.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2027187&amp;key=10.1056%2FNEJMoa1810171&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30280657/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450816900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Brigatinib+versus+crizotinib+in+ALK-positive+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2027-2039&amp;doi=10.1056%2FNEJMoa1810171&amp;pmid=30280657" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] potent second-generation ALK inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] of progression or death than crizotinib. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Selvaggi G, Wakelee HA, Mok T, et al. Phase III randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (<i>ALK</i>) positive NSCLC patients: EXALT3. Presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer, Singapore, August 8, 2020. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Selvaggi+G%2C+Wakelee+HA%2C+Mok+T%2C+et+al.+Phase+III+randomized+study+of+ensartinib+vs+crizotinib+in+anaplastic+lymphoma+kinase+%28ALK%29+positive+NSCLC+patients%3A+EXALT3.+Presented+at+the+International+Association+for+the+Study+of+Lung+Cancer+World+Conference+on+Lung+Cancer%2C+Singapore%2C+August+8%2C+2020.+abstract." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for disease progression or death of 0.51. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] of progression or death than crizotinib. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] were 38%, 28%, and 27%, respectively. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the <i>EML4-ALK</i> fusion variant on the efficacy of alectinib in untreated <i>ALK</i>-positive advanced non-small cell lung cancer in the global Phase III ALEX Study. <em>J Thorac Oncol</em> 2019;14:1233-1243.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2019.03.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30902613/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000472506000022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Updated+efficacy+and+safety+data+and+impact+of+the+EML4-ALK+fusion+variant+on+the+efficacy+of+alectinib+in+untreated+ALK-positive+advanced+non-small+cell+lung+cancer+in+the+global+Phase+III+ALEX+Study.&amp;publication_year=2019&amp;journal=J+Thorac+Oncol&amp;pages=1233-1243&amp;doi=10.1016%2Fj.jtho.2019.03.007&amp;pmid=30902613" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] events than crizotinib (45% vs. 51%). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naive <i>ALK</i>-positive non-small cell lung cancer: second interim analysis of the Phase III ALTA-1L trial. <em>J Clin Oncol</em> 2020 August 11 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.20.00505" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32780660/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000588411100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Brigatinib+versus+crizotinib+in+advanced+ALK+inhibitor-naive+ALK-positive+non-small+cell+lung+cancer%3A+second+interim+analysis+of+the+Phase+III+ALTA-1L+trial.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;doi=10.1200%2FJCO.20.00505&amp;pmid=32780660" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to crizotinib as first-line therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for disease progression or death of 0.49. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] were 38%, 28%, and 27%, respectively. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] 3 or higher than crizotinib (73% vs. 61%), </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in <i>ALK</i>-rearranged lung cancer. <em>Cancer Discov</em> 2016;6:1118-1133.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/2159-8290.CD-16-0596" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27432227/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385642200022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Molecular+mechanisms+of+resistance+to+first-+and+second-generation+ALK+inhibitors+in+ALK-rearranged+lung+cancer.&amp;publication_year=2016&amp;journal=Cancer+Discov&amp;pages=1118-1133&amp;doi=10.1158%2F2159-8290.CD-16-0596&amp;pmid=27432227" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] drug resistance and recurrent disease </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] mutations that have been identified. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] first- or second-generation inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] receiving second-generation inhibitors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Katayama R, Friboulet L, Koike S, et al. Two novel <i>ALK</i> mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. <em>Clin Cancer Res</em> 2014;20:5686-5696.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-14-1511" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25228534/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345130800014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Two+novel+ALK+mutations+mediate+acquired+resistance+to+the+next-generation+ALK+inhibitor+alectinib.&amp;publication_year=2014&amp;journal=Clin+Cancer+Res&amp;pages=5686-5696&amp;doi=10.1158%2F1078-0432.CCR-14-1511&amp;pmid=25228534" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Dagogo-Jack I, Oxnard GR, Fink J, et al. A phase II study of lorlatinib in patients (pts) with <i>ALK</i>-positive (ALK+) lung cancer with brain-only progression. <em>J Clin Oncol</em> 2020;38:Suppl 15:9595-9595. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2020.38.15_suppl.9595" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+II+study+of+lorlatinib+in+patients+%28pts%29+with+ALK-positive+%28ALK%2B%29+lung+cancer+with+brain-only+progression&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=9595-9595&amp;doi=10.1200%2FJCO.2020.38.15_suppl.9595" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cause of illness and death — still develop. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] disease, including leptomeningeal disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Bauer TM, Shaw AT, Johnson ML, et al. Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated <i>ALK</i>-positive non-small-cell lung cancer. <em>Target Oncol</em> 2020;15:55-65.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11523-020-00702-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32060867/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000514800300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Brain+penetration+of+lorlatinib%3A+cumulative+incidences+of+CNS+and+non-CNS+progression+with+lorlatinib+in+patients+with+previously+treated+ALK-positive+non-small-cell+lung+cancer.&amp;publication_year=2020&amp;journal=Target+Oncol&amp;pages=55-65&amp;doi=10.1007%2Fs11523-020-00702-4&amp;pmid=32060867" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cause of illness and death — still develop. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] disease, including leptomeningeal disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Gainor JF, Chi AS, Logan J, et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. <em>J Thorac Oncol</em> 2016;11:256-260.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2015.10.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26845119/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373094300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Alectinib+dose+escalation+reinduces+central+nervous+system+responses+in+patients+with+anaplastic+lymphoma+kinase-positive+non-small+cell+lung+cancer+relapsing+on+standard+dose+alectinib.&amp;publication_year=2016&amp;journal=J+Thorac+Oncol&amp;pages=256-260&amp;doi=10.1016%2Fj.jtho.2015.10.010&amp;pmid=26845119" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. <em>Curr Oncol</em> 2013;20(4):e300-e306.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3747/co.20.1481" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23904768/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000322782400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Survival+of+patients+with+non-small-cell+lung+cancer+after+a+diagnosis+of+brain+metastases.&amp;publication_year=2013&amp;journal=Curr+Oncol&amp;pages=e300-e306&amp;doi=10.3747%2Fco.20.1481&amp;pmid=23904768" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Venur VA, Ahluwalia MS. Targeted therapy in brain metastases: ready for primetime? <em>Am Soc Clin Oncol Educ Book</em> 2016;35:e123-e130.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/EDBK_100006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27249714/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeted+therapy+in+brain+metastases%3A+ready+for+primetime%3F&amp;publication_year=2016&amp;journal=Am+Soc+Clin+Oncol+Educ+Book&amp;pages=e123-e130&amp;doi=10.1200%2FEDBK_100006&amp;pmid=27249714" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. <em>Cancer Cell</em> 2015;28:70-81.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ccell.2015.05.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26144315/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358111300011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PF-06463922%2C+an+ALK%2FROS1+inhibitor%2C+overcomes+resistance+to+first+and+second+generation+ALK+inhibitors+in+preclinical+models.&amp;publication_year=2015&amp;journal=Cancer+Cell&amp;pages=70-81&amp;doi=10.1016%2Fj.ccell.2015.05.010&amp;pmid=26144315" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations that have been identified. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] first- or second-generation inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] effective in treating CNS metastases. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Horn L, Whisenant JG, Wakelee H, et al. Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. <em>J Thorac Oncol</em> 2019;14:1901-1911.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2019.08.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31446141/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000492678300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Monitoring+therapeutic+response+and+resistance%3A+analysis+of+circulating+tumor+DNA+in+patients+with+ALK%2B+lung+cancer.&amp;publication_year=2019&amp;journal=J+Thorac+Oncol&amp;pages=1901-1911&amp;doi=10.1016%2Fj.jtho.2019.08.003&amp;pmid=31446141" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations that have been identified. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] first- or second-generation inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] receiving second-generation inhibitors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10<i>R</i>)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2<i>H</i>-8,4-(metheno)pyrazolo[4,3-<i>h</i>][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. <em>J Med Chem</em> 2014;57:4720-4744.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1021/jm500261q" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24819116/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000337336600023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations.&amp;publication_year=2014&amp;journal=J+Med+Chem&amp;pages=4720-4744&amp;doi=10.1021%2Fjm500261q&amp;pmid=24819116" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] order to achieve high exposures in the CNS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] tropomyosin receptor kinase B in the CNS. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with <i>ALK</i> or <i>ROS1</i> rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <em>Lancet Oncol</em> 2017;18:1590-1599.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(17)30680-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29074098/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417001900038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lorlatinib+in+non-small-cell+lung+cancer+with+ALK+or+ROS1+rearrangement%3A+an+international%2C+multicentre%2C+open-label%2C+single-arm+first-in-man+phase+1+trial.&amp;publication_year=2017&amp;journal=Lancet+Oncol&amp;pages=1590-1599&amp;doi=10.1016%2FS1470-2045%2817%2930680-0&amp;pmid=29074098" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] order to achieve high exposures in the CNS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] second-generation, or both). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 1 and reversible with dose interruption. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] effective in treating CNS metastases. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] to that reported in previous studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] with dose interruption and reduction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with <i>ALK</i>-positive non-small-cell lung cancer: results from a global phase 2 study. <em>Lancet Oncol</em> 2018;19:1654-1667.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(18)30649-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30413378/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451633800060" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lorlatinib+in+patients+with+ALK-positive+non-small-cell+lung+cancer%3A+results+from+a+global+phase+2+study.&amp;publication_year=2018&amp;journal=Lancet+Oncol&amp;pages=1654-1667&amp;doi=10.1016%2FS1470-2045%2818%2930649-1&amp;pmid=30413378" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] second-generation, or both). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] disease, including leptomeningeal disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 1 and reversible with dose interruption. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] resistance mutations. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] ranging from 14.5 months to not reached. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] response was even higher, at 87%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] to that reported in previous studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] with dose interruption and reduction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys <i>BRAF</i>-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <em>Lancet Oncol</em> 2012;13:1087-1095.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(12)70431-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23051966/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000310570900039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dabrafenib+in+patients+with+Val600Glu+or+Val600Lys+BRAF-mutant+melanoma+metastatic+to+the+brain+%28BREAK-MB%29%3A+a+multicentre%2C+open-label%2C+phase+2+trial.&amp;publication_year=2012&amp;journal=Lancet+Oncol&amp;pages=1087-1095&amp;doi=10.1016%2FS1470-2045%2812%2970431-X&amp;pmid=23051966" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib. <em>Oncologist</em> 2019;24:1103-1110.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.2018-0380" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30890623/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000481426100036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+management+of+adverse+events+associated+with+lorlatinib.&amp;publication_year=2019&amp;journal=Oncologist&amp;pages=1103-1110&amp;doi=10.1634%2Ftheoncologist.2018-0380&amp;pmid=30890623" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 1 and reversible with dose interruption. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with dose interruption and reduction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] may be associated with increased appetite. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] Supplementary Appendix). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Reed M, Rosales A-LS, Chioda MD, Parker L, Devgan G, Kettle J. Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. <em>Adv Ther</em> 2020;37:3019-3030.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12325-020-01365-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32399810/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000532097000004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Consensus+recommendations+for+management+and+counseling+of+adverse+events+associated+with+lorlatinib%3A+a+guide+for+healthcare+practitioners.&amp;publication_year=2020&amp;journal=Adv+Ther&amp;pages=3019-3030&amp;doi=10.1007%2Fs12325-020-01365-3&amp;pmid=32399810" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 1 and reversible with dose interruption. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with dose interruption and reduction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Supplementary Appendix). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Soria J-C, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced <i>ALK</i>-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <em>Lancet</em> 2017;389:917-929.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)30123-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28126333/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000395263400031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+ceritinib+versus+platinum-based+chemotherapy+in+advanced+ALK-rearranged+non-small-cell+lung+cancer+%28ASCEND-4%29%3A+a+randomised%2C+open-label%2C+phase+3+study.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=917-929&amp;doi=10.1016%2FS0140-6736%2817%2930123-X&amp;pmid=28126333" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Shaw AT, Solomon BJ, Besse B, et al. <i>ALK</i> resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. <em>J Clin Oncol</em> 2019;37:1370-1379.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.18.02236" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30892989/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471946600003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ALK+resistance+mutations+and+efficacy+of+lorlatinib+in+advanced+anaplastic+lymphoma+kinase-positive+non-small-cell+lung+cancer.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=1370-1379&amp;doi=10.1200%2FJCO.18.02236&amp;pmid=30892989" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. <em>J Clin Oncol</em> 2011;29(15):e443-e445.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2010.34.1313" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21422405/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000290716900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CSF+concentration+of+the+anaplastic+lymphoma+kinase+inhibitor+crizotinib.&amp;publication_year=2011&amp;journal=J+Clin+Oncol&amp;pages=e443-e445&amp;doi=10.1200%2FJCO.2010.34.1313&amp;pmid=21422405" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced <i>ROS1</i>-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. <em>Lancet Oncol</em> 2019;20:1691-1701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(19)30655-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31669155/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500750400049" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lorlatinib+in+advanced+ROS1-positive+non-small-cell+lung+cancer%3A+a+multicentre%2C+open-label%2C+single-arm%2C+phase+1-2+trial.&amp;publication_year=2019&amp;journal=Lancet+Oncol&amp;pages=1691-1701&amp;doi=10.1016%2FS1470-2045%2819%2930655-2&amp;pmid=31669155" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Drilon A. TRK inhibitors in TRK fusion-positive cancers. <em>Ann Oncol</em> 2019;30:Suppl 8:viii23-viii30.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz282" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31738426/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000501727600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TRK+inhibitors+in+TRK+fusion-positive+cancers.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=viii23-viii30&amp;doi=10.1093%2Fannonc%2Fmdz282&amp;pmid=31738426" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879496/radiation-oncologist-texas-oncology-el-paso/?query=fjwp&amp;rid=5696">Radiation Oncologist - Texas Oncology El Paso</a></div></div><div class="nejm-widget_item"><div><span> Weymouth, Massachusetts</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/875947/primary-care-family-medicine-weymouth-ma/?query=fjwp&amp;rid=980">Primary Care - Family Medicine - Weymouth, MA</a></div></div><div class="nejm-widget_item"><div><span> Coal Township, Pennsylvania</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886386/non-invasive-cardiologist/?query=fjwf&amp;rid=764">Non-Invasive Cardiologist</a></div></div><div class="nejm-widget_item"><div><span> Seattle, Washington State</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887267/primary-care-physician-fm-fm-ob-optum-madison-center-seattle-wa/?query=fjwf&amp;rid=220874">Primary Care Physician (FM, FM/OB) - Optum Madison Center, Seattle, WA</a></div></div><div class="nejm-widget_item"><div><span> Loma Linda, California</span></div><div><span>Ophthalmology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883949/academic-neuro-ophthalmologist-opportunity-in-southern-california/?query=fjwp&amp;rid=69418">Academic Neuro-Ophthalmologist Opportunity in Southern California</a></div></div><div class="nejm-widget_item"><div><span> Athens, Ohio</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887375/ob-gyn-hospitalist/?query=fjwf&amp;rid=49812">OB/GYN Hospitalist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2027187&amp;pubId=41289288&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d656d4e3c0af23-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d656d4e3c0af23-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d656d4e3c0af23-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$818665448$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$818665448$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$818665448$--></div></div><div class="mlt-body"><!--?lit$818665448$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$818665448$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$818665448$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$818665448$-->Jun 13, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2402419?query=recirc_Semantic" target="_self">Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin</a></div><div class="mlt-article-authors"><!--?lit$818665448$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$818665448$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$818665448$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$818665448$-->Apr 11, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2402015?query=recirc_Semantic" target="_self">Adjuvant Alectinib in <em>ALK</em>-Rearranged NSCLC — Here and Now</a></div><div class="mlt-article-authors"><!--?lit$818665448$-->A. Passaro and S. Peters</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$818665448$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$818665448$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$818665448$-->Aug 19, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2101264?query=recirc_Semantic" target="_self">Lorlatinib in a Child with <em>ALK</em>-Fusion–Positive High-Grade Glioma</a></div><div class="mlt-article-authors"><!--?lit$818665448$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$818665448$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$818665448$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$818665448$-->Jan 11, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2302299?query=recirc_Semantic" target="_self">Repotrectinib in <em>ROS1</em> Fusion–Positive Non–Small-Cell Lung Cancer</a></div><div class="mlt-article-authors"><!--?lit$818665448$-->A. Drilon and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$818665448$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$818665448$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$818665448$-->Apr 11, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2310532?query=recirc_Semantic" target="_self">Alectinib in Resected <em>ALK</em>-Positive Non–Small-Cell Lung Cancer</a></div><div class="mlt-article-authors"><!--?lit$818665448$-->Y.-L. Wu and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2027187?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2027187" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2027187.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2027187"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung Cancer</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2006136" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2022926" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f1.jpg"><img src="/cms/10.1056/NEJMoa2027187/asset/36201cc3-90d7-4f2c-af4e-53d9075534ee/assets/images/large/nejmoa2027187_f1.jpg" height="3097" width="2231" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Randomization, Treatment, and Follow-up.</div><div class="notes"><div role="doc-footnote">A total of 296 patients were randomly assigned to receive either lorlatinib or crizotinib. The intention-to-treat population included all the patients who underwent randomization. The as-treated population included all the patients who received at least one dose of lorlatinib or crizotinib.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2027187_f2.jpg"><img src="/cms/10.1056/NEJMoa2027187/asset/19964ad5-4b64-455b-8a1f-7888ee796a58/assets/images/large/nejmoa2027187_f2.jpg" height="3374" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Efficacy Outcomes in the Intention-to-Treat Population.</div><div class="notes"><div role="doc-footnote">Panel A shows Kaplan–Meier estimates of progression-free survival, according to blinded independent central review (BICR) in the intention-to-treat population. Progression-free survival was significantly longer with lorlatinib than crizotinib; the median progression-free survival with lorlatinib was not reached. Tick marks on the survival curves indicate censoring of data. NR denotes not reached. Panel B shows Kaplan–Meier estimates of time to intracranial progression, as assessed by BICR, in the intention-to-treat population. Time to intracranial progression was defined as the time from randomization to the first objective progression of central nervous system (CNS) disease (either new brain metastases or progression of existing brain metastases). Panel C shows the cumulative incidence of CNS progression as the first event, as assessed by BICR in the intention-to-treat population. Cumulative-incidence probabilities were calculated with the use of a competing-risks approach, with values adjusted for the competing risks of non-CNS progression and death (Fig. S3 in the <a href="#ap2">Supplementary Appendix</a>). Panel D shows Kaplan–Meier curves of overall survival.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Baseline Patient Characteristics in the Intention-to-Treat Population.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Objective Response in the Intention-to-Treat Population and among Patients with Brain Metastases at Baseline.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events in the Safety Population.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/21" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 21</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 19, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2022926" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">The RECOVERY Collaborative Group</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 19, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2006136" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T. Quattrin and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 19, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2019014" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.B. Cavalcanti and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2027187%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2027187&amp;pubId=41289288&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2027187%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2027187&amp;pubId=41289288&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id048950961218719413" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d656d4e3c0af23-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d656d4e3c0af23-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d656d4e3c0af23-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d656d4e3c0af23-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d656d4e3c0af23-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d656d4e3c0af23-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d656d4e3c0af23-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d656d4e3c0af23-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d656d4e3c0af23-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d656d4e3c0af23-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d656d4dad7af23',t:'MTc0OTUzMTk4NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d656d4dad7af23&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><znx-nycopzhbpydg></znx-nycopzhbpydg><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2027187?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><iframe name="captureIFrame_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-transactionid="cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" id="captureIFrame_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" target="captureIFrame_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="capture_screen"><input id="capture_signIn_js_version_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="js_version"><input id="capture_signIn_transactionId_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" type="hidden" class="capture_transactionId_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="capture_transactionId"><input id="capture_signIn_form_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="form"><input id="capture_signIn_flow_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="flow"><input id="capture_signIn_client_id_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="client_id"><input id="capture_signIn_redirect_uri_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="redirect_uri"><input id="capture_signIn_response_type_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="response_type"><input id="capture_signIn_flow_version_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="flow_version"><input id="capture_signIn_settings_version_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="settings_version"><input id="capture_signIn_locale_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="locale"><input id="capture_signIn_recaptcha_version_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_cj7n5ofqzv25r62ls5pa6sqvqa0bealf0hscz4mu" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>